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ABSTRACT

February 2021
Seok-Yeong Yu,
B.S., KANGOWN NATIONAL UNIVERSITY, CHUNCHEON, SOUTH KOREA
M.S., UNIVERSITY OF MASSACHUSETTS AMHERST
Ph.D., UNIVERSITY OF MASSACHUSETTS AMHERST
Directed by Dr. Young-Cheul Kim, Department of Nutrition

Obesity is a serious health problem in the U.S. and worldwide and is associated
with non-alcoholic fatty liver disease (NAFLD), type 2 diabetes mellitus (T2DM) and
cardiovascular disease (CVD). Observational studies have also shown an inverse
relationship between obesity and reduced bioavailability of fat-soluble vitamins, which
is due in part to increased sequestration in expanded adipose tissue (AT). AT serves as
the primary site of storage organ for excess energy, however, in morbid obesity
enlarged adipocytes exhibit decreased lipid uptake, impaired lipid hydrolysis and
oxidation and increased inflammation, which are collectively referred to as AT
dysfunction. Substantial evidence characterizes AT dysfunction as a central mechanism
leading to the development of metabolic comorbidities, such as chronic inflammation,
hepatic steatosis, and insulin resistance. However, there is very little information
regarding the molecular mechanisms that mediate AT dysfunction in obesity. Moreover,
there are few intervention approaches and treatment options against AT dysfunction.
Through the dissertation work, we have identified four dietary bioactives that
mitigate obesity-induced AT dysfunction, including extracts from aronia berries and
cranberries, sulforaphane and formononetin, with potential underlying mechanisms
identified for each bioactive using in vivo and/or in vitro models. In addition, using
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C57BL/6 mice with a genetic knockout of tumor necrosis factor alpha (TNFα KO), we
have characterized the impact of the genetic ablation of TNFα, a potent mediator of
tissue and systemic inflammation, on fatty acid metabolism and inflammation in AT
and the liver during the development of a high-fat diet (HFD)-induced obesity. We
found that TNFα KO mitigates HFD-induced impairments of lipid hydrolysis and fatty
acid oxidation (FAO) and expression of inflammatory markers in AT with concomitant
improvements of adiposity, hepatic steatosis, and insulin resistance in these mice. This
suggests that obesity-induced TNFα serves as a potential mediator of AT dysfunction.
Furthermore, our in vivo and in vitro findings indicate that TNFα downregulates the
expression of genes related to FAO in adipocytes by suppressing the conversion of
retinol (dietary vitamin A) to retinoic acid (RA), which is a potential endogenous
agonist of the transcriptional factor peroxisome proliferator-activated receptor
beta/delta (PPARβ/δ) for inducing genes related to FAO. The treatment of exogenous
RA, on the other hand, significantly increased adipocyte FAO in TNFα-treated 3T3-L1
adipocytes. RA treatment also suppressed the expression of pro-inflammatory genes in
RAW264.7 macrophages stimulated with adipocyte-conditioned media by increasing
PPARβ/δ protein expression in both cell types.
Taken together, these findings provide a biochemical and molecular basis for
planning future studies to test clinical relevance and also for developing therapeutic
interventions against obesity-induced AT dysfunction and related metabolic
complications.
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CHAPTER
1. Literature Review
1.1. Obesity and Adipose Tissue Dysfunction
1.1.1. Prevalence, Complications, and Causes
Obesity is characterized by excessive adiposity in the body and is generally
defined by body mass index [BMI, body weight (kg) / height (m2)] for adults with three
classifications: normal weight (BMI 18.50 to 24.99 kg/m2), overweight (BMI 25.00 to
29.99 kg/m2) and obese (BMI ≥30 kg/m2). For children aged 2 through 19 years, obesity
is defined based on the World Health Organization (WHO) Child Growth Standards
due to the variations in growth, sex and sexual development and maturation, all of
which affect body composition in children (Adela & Hu, 2015). Given the distribution
of growth, normal weight is in the range between -2 and 1 standard deviation (S.D.),
overweight in the range of >1 to ≤2 S.D. and obese is greater than >2 S.D.
The prevalence of obesity has been tripled in the U.S. since 1975, and
approximately 40% of adults are considered obese in 2017-2018 (Craig M. Hales,
Margaret D. Carroll, Cheryl D. Fryar, 2020). In addition, the prevalence of obesity in
children remarkably increased, affecting about 18.5% of children and adolescents in
the U.S. (Anderson, Butcher, & Schanzenbach, 2019). Based on the predictive model,
the increasing trend in childhood obesity foretells that nearly half of the U.S. adult
population will be obese by 2030 (Finkelstein et al., 2012). Also, rising obesity rates
place heavy economic burdens on healthcare costs through medical expenditure and
lost productivity (Finkelstein, DiBonaventura, Burgess, & Hale, 2010). In adults, the
annual cost of obesity is estimated to be $1,500 to $2,700 per capita compared to lean
individuals in 2006 (Finkelstein, Trogdon, Cohen, & Dietz, 2009). The co-presence of
obesity and its related complications such as type 2 diabetes mellitus (T2DM) and
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cardiovascular disease (CVD) burdens even more about $9,000 to $17,000 per capita
(Fernandes, 2010). Obesity prevalence differs across ethnic and racial groups in the U.S.
In adults, obesity prevalence is highest among non-Hispanic black (49.6%) and
Hispanic (44.8%) followed by non-Hispanic white (42.2%) and non-Hispanic Asian
(17.4%) (Craig M. Hales, Margaret D. Carroll, Cheryl D. Fryar, 2020). Consistent
tendency exists in childhood obesity, affecting Hispanics (25.8%) and non-Hispanic
black (22.0%) the most, followed by non-Hispanic white (14.1%) and non-Hispanic
Asians (11.0%) (Fryar, Carroll, & Ogden, 2018). To understand racial/ethnic disparities
in obesity prevalence, various social and environmental factors have been identified,
including, but not limited to, social economic status (SES), education, stress and food
desert (Brehm & D’Alessio, 2000). Those factors show correlations with the preference
and intake of energy-dense and nutrient-poor diets and low physical activity, thus
contributing to racial/ethnic disparities in the prevalence of obesity (Brehm &
D’Alessio, 2000).
Obesity is a significant risk factor for the leading causes of death in the U.S.,
including non-alcoholic fatty liver disease (NAFLD), T2DM and CVD (Ellulu, Patimah,
Khaza’ai, Rahmat, & Abed, 2017). This is strongly supported by accumulating
evidence that obesity leads to the development of metabolic comorbidities such as
chronic low-grade inflammation, disturbed lipid metabolism in tissues, and systemic
insulin resistance, all of which are recognized as etiologic factors for the chronic
diseases (Daryabor, Kabelitz, & Kalantar, 2019; Kahn, Hull, & Utzschneider, 2006). In
addition, epidemiological studies have demonstrated the inverse relationship between
BMI and vitamin status, especially fat-soluble vitamins, by measuring serum
concentrations of 25-hydroxyvitamin D, retinol and its metabolite retinoic acid (RA)
(Bøhmer, Aasheim, Hofsø, Hjelmesæth, & Birkeland, 2018; Liu, Chen, Mu, Fan, et al.,
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2016; Thomas-Valdés, Tostes, Anunciação, da Silva, & Sant’Ana, 2017). This
relationship is often associated with low intakes of fat-soluble vitamins and increased
sequestration into expanded adipose tissue (AT) (Bøhmer et al., 2018). In this regard,
it was reported that retinol concentration was significantly increased in tissues such as
the liver, kidney and AT in diet-induced obese mice compared to lean mice (M. Zhang
et al., 2015). Furthermore, obese mice exhibited decreased expression levels of genes
involved in the oxidation of retinol into RA and had lower concentrations of RA in AT
(Sugii, Olivo, Sriram, Perumal, & Lim, 2016; Trasino, Tang, Jessurun, & Gudas, 2015).
These observations indicate that obesity increases retinol deposition and reduces RA
bioavailability in AT. However, it still remains unclear whether reduced RA
bioavailability is one of obesity-induced outcomes or promotes the development of
obesity-induced metabolic disorders.
Body fat mass is determined by the balance between energy input and energy
output. Excessive adiposity is a metabolic outcome of having a surplus energy balance
for a prolonged period of time. Major risk factors for the development of obesity
include hypercaloric diets (a high fat and/or high sugar diet), low consumption of fruits
and vegetables and physical inactivity (Pérez-Martínez et al., 2017). In addition, a
growing body of evidence indicates that inflammation promotes adiposity. Boaz et. al.
demonstrated that the use of anti-inflammatory interventions such as aspirin and statins
was significantly associated with weigh loss in patients with T2DM (Boaz, Lisy,
Zandman-Goddard, & Wainstein, 2009). It was also observed that the treatment of the
anti-inflammatory and anti-allergic drug, Amlexanox, for 12 weeks mitigated body
weight with a significant reduction in hepatic fat contents in patients with T2DM (Oral
et al., 2017). In accordance with the observations in humans, it was shown in mice that
nuclear factor kappa B (NF-κB) signaling, which induces pro-inflammatory genes, is
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activated in tissues during the development of diet-induced obesity (Carlsen et al.,
2009), whereas the inhibition of NF-κB signaling by butein, a potent NF-κB inhibitor,
prevented HFD-induced adiposity and insulin resistance (Benzler et al., 2015).
Moreover, the genetic ablation of tumor necrosis factor alpha (TNFa), a key mediator
of tissue inflammation, attenuated HFD-induced adiposity, insulin resistance and blood
lipids in mice (Bouter, Geary, Langhans, & Asarian, 2010). These observations thus
point to a critical role that inflammation plays in the development of obesity and related
metabolic disturbances.
1.1.2. The Physiological Role of Adipose Tissue (AT)
Adipose tissue (AT) serves as a primary energy reservoir of the body by storing
extra energy in the form of triglyceride (TG) in adipocytes (Church, Horowitz, &
Rodeheffer, 2012). A certain portion of energy then is directed to the liver. For example,
about 70% of dietary fats are hydrolyzed and taken up by AT, and the rest, ~30%, is
sequestered by the liver (Duwaerts & Maher, 2019). During fasting state, metabolic
demand in AT is geared towards TG hydrolysis and oxidation of free fatty acids (FFAs),
some of which are also released out to peripheral tissues. AT has limits with regard to
expandability and capacity to store lipids in humans (P. Arner et al., 2011; Duwaerts &
Maher, 2019; Rydén, Andersson, Bernard, Spalding, & Arner, 2013; Spalding et al.,
2008). Therefore, adipocyte lipid turnover through lipid hydrolysis and oxidation
serves as an important mechanism for AT to maintain its metabolic capacity and
flexibility.
TG hydrolysis in adipocytes is mediated by hormone-mediated lipolysis, which
involves the translocation of intracellular lipases, such as hormone-sensitive lipase
(HSL) and adipose triglyceride lipase (ATGL), to lipid droplets (LDs) in the cytosol
(Martin et al., 2009). ATGL has a selective specificity for TG, but not for
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diacylglycerols (DGs) and monoacylglycerols (MGs), whereas HSL does have
activities for all. The translocation/activation of HSL to LDs is regulated by
phosphorylation at serine (Ser) residues. In a quiescent state, HSL is phosphorylated at
Ser 565 (pHSL565) (Kershaw et al., 2006). Upon cyclic AMP (cAMP) elevation, HSL
undergoes phosphorylation at Ser 660 (pHSL66) and translocate to and hydrolyze LDs
in the cytosol (Bézaire, Mairal, Anesia, Lefort, & Langin, 2009). Further
phosphorylation at Ser 563 is shown to remove the phosphoryl group at Ser 565. Then,
hydrolyzed FAs through hormone-mediated lipolysis will enter mitochondria to be
oxidized through carnitine palmitoyltransfease 1 (CPT1)-mediated pathway with some
of FFAs released out of cells (Schulz, 2013).
AT is largely composed of adipocytes and stomal vascular fraction (SVF),
which contains multiple cell types, including macrophages, multipotent stem cells, and
preadipocytes (Bora & Majumdar, 2017). AT maintains metabolically active
adipocytes by generating new adipocytes from precursor cells. In humans, it was
reported using C14 isotope that about 10% of adipocytes per year is replaced by new
adipocytes (Spalding et al., 2008). The new adipocyte generation, which is commonly
referred to as adipogenesis, is well characterized by studies using immortalized
preadipocyte or multipotent stem cell lines such as 3T3-L1 cells and 10T1/2 cells.
Adipogenesis involves the recruitment of stem cells and their commitment to
preadipocytes, followed by differentiation into adipocytes (Cawthorn, Heyd, Hegyi, &
Sethi, 2007; Ntambi & Young-Cheul, 2000). At the molecular level, it was revealed
that Wnt/β-catenin activation mediates the commitment of stem cells to preadipocytes,
and transient deactivation induces the expression of key adipogenic transcriptional
factors such as peroxisome proliferator-activated receptor gamma (PPARγ) and
CCAAT/enhancer-binding protein alpha (C/EBPα). The coordinated actions of these
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transcription factors then lead to the late stage of adipogenesis through the
transactivation of adipogenic target genes such as glucose transporter 4 (GLUT4),
adiponectin, and fatty acid synthase (FAS).
Macrophages are commonly called resident macrophages located in adipose
SVF since born (Zhao, Zou, Du, & Zhao, 2018; C. Zheng et al., 2016). In lean state,
resident macrophages stay quiescent and are constantly replenished by recruiting bone
marrow-originated monocytes from the circulation and differentiating into
macrophages (Zhao et al., 2018; C. Zheng et al., 2016). Macrophages play an important
role in facilitating tissue immune function. Macrophage plasticity allows them to adapt
to changing microenvironment (Mohammadi et al., 2019). For example, inflammatory
stimuli including lipopolysaccharide (LPS) and TNFα promote the polarization of
macrophages into inflammatory macrophages, which engulf foreign pathogens and
damaged cells, whereas anti-inflammatory stimuli such as IL-4 and IL-10 induce antiinflammatory macrophages responsible for the resolution of tissue inflammation and
repair (Morris, Singer, & Lumeng, 2011; Watanabe, Alexander, Misharin, & Budinger,
2019).

1.1.3. AT Dysfunction in Obesity
In severe obesity, AT exhibits decreased lipid turnover and reduced lipid uptake
(Frayn, Bernard, Spalding, & Arner, 2012; McQuaid et al., 2011; Rydén et al., 2013).
When compared to lean subjects, AT lipid age is significantly older in obese individuals
demonstrated by measuring the retention time of fatty acids with C14 isotope (Rydén et
al., 2013). cAMP-induced lipolysis rates were decreased with increasing BMI and
inversely correlated with lipid retention in AT (Rydén et al., 2013). Moreover, it was
reported that stimulated lipolysis and HSL expression were suppressed in AT explants
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from obese donors, when compared to lean donors (Langin et al., 2005). In addition to
decreased lipid turnover, lipid retention time in AT is correlated with adipocyte cell
volume, BMI and blood lipid concentrations in obese individuals (P. Arner et al., 2011;
Frayn et al., 2012; McQuaid et al., 2011; Rydén et al., 2013). In this regard, McQuaid
et. al. traced [2H2] palmitate and found that decreased lipid uptake of AT increases the
concentration of blood lipids and hepatic fat accommodation in obese men (McQuaid
et al., 2011) compared to lean men. These observations indicate that decreased lipid
turnover of AT in obesity can be attributable to hyperlipidemia and hepatic steatosis.
As a potential mediator of disrupted hormone-mediated lipolysis, accumulated
evidence suggests tumor necrosis factor alpha (TNF), which is overexpressed in AT
in obesity (Hotamisligil, Arner, Caro, Atkinson, & Spiegelman, 1995; Hotamisligil GS,
Shargill NS, & Spiegelman BM, 1993; Parameswaran & Patial, 2010). It was observed
that TNF suppresses the mRNA expression levels of HSL and ATGL in 3T3-L1
adipocytes (Ruan, Hacohen, Golub, Van Parijs, & Lodish, 2002). Consistently, Bézaire
et. al. have demonstrated that TNF suppresses the protein expression levels of HSL
and ATGL in human multipotent adipose tissue-derived stem cells (hMADS cells) and
also inhibited cAMP stimulated-lipolysis, while promoting FFA release out of cells
through basal lipolysis (Bézaire et al., 2009). Inducing nuclear NF-B activation and/or
c-Jun N-terminal kinase (JNK) activation are suggested as potential molecular
mechanisms for disrupted lipolysis in adipocytes by TNF (Laurencikiene et al., 2007).
Also, the findings that TNF suppresses condensation of mitochondria and reduced
ATP production in 3T3-L1 adipocytes would explain the increased release of FFAs by
TNF through basal lipolysis (Chen et al., 2010). Therefore, these observations support
the inhibitory roles of obesity-induced TNF in lipid hydrolysis/oxidation in
adipocytes.
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Obesity leads to changes in cellular composition in AT. Isakson et. al. have
demonstrated that subcutaneous preadipocyte differentiation is significantly decreased
as BMI increases (Isakson, Hammarstedt, Gustafson, & Smith, 2009a). Low generation
rates of new fat cells were correlated with adipocyte cell volume in humans (Isakson et
al., 2009a). Moreover, the expression of subcutaneous PPARγ, which is a key
transcriptional regulator of adipogenesis, and its downstream target genes (GLUT4,
adiponectin and FAS) was significantly downregulated in obese individuals when
compared to non-obese subjects (Geagea et al., 2018; Martínez-Jiménez et al., 2019).
Therefore, it was suggested that decreased adipogenesis would impose metabolic
burden to existing adipocytes in AT in obesity (E. Arner et al., 2010). In addition, obese
individuals had significantly a high number of circulating monocytes in blood and
increased accumulation of macrophages in AT when compared to lean subjects
(Wouters et al., 2017). While macrophage accounts for about 5% of the cells in AT in
lean mice, 50% of AT is composed of macrophages in obesity (Boutens & Stienstra,
2016), making AT as a primary source of inflammation in obesity.
The consequences of impaired adipogenesis and disrupted lipolysis correlate
with increased tissue inflammation in AT in obesity (Frayn et al., 2012). Obesity
exhibits increased proliferation of resident macrophages and recruitment of
monocytes/macrophages from bone marrow in AT (C. Zheng et al., 2016). In mice,
HFD significantly increased the number of macrophages as well as both types of
polarized macrophages but preferentially pro-inflammatory macrophages over antiinflammatory macrophages (C. Zheng et al., 2016). In addition, it was demonstrated
that obese individuals have increased accumulation of inflammatory macrophages in
AT and increasingly secreted proinflammatory cytokines, such as TNFα, monocyte
chemoattractant protein-1 (MCP-1) and interleukin-6 (IL-6) from AT (D. A. Hill et al.,
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2018; Makki, Froguel, & Wolowczuk, 2013; Wu et al., 2010). As potential stimuli for
promoting inflammatory macrophage polarization, adipocytes-originated FFAs and
reactive oxygen species (ROS) were suggested (Chitraju et al., 2017). In addition, a
growing body of in vivo evidence indicates that HFD and/or HFD-induced endotoxemia
results in high levels of luminal bacteria in the circulation, inducing tissue and systemic
inflammation (Bouter et al., 2010; Cani et al., 2007)
Taken together, substantial evidence indicates that AT in obesity is
dysfunctional, exhibiting promoted macrophage accumulation & inflammation and
disturbed lipid metabolism, together with impaired adipogenesis and disrupted both
hormone-mediated lipolysis and FAO in adipocytes. Moreover, AT dysfunction
elevates blood lipids and fat deposition in non-ATs especially the liver, suggesting AT
dysfunction as a central mechanism for obesity-induced metabolic comorbidities such
as chronic inflammation, hepatic steatosis and insulin resistance.

1.1.4. Knowledge gap in the pathogenesis of AT dysfunction
Obesity is a significant risk factor for the leading causes of death such as
NAFLD, T2DM and CVD. Substantial evidence characterizes AT dysfunction in
obesity as a central mechanism leading to metabolic comorbidities such as insulin
resistance and chronic inflammation. However, little has been appreciated regarding
potential mechanisms by which obesity develops AT dysfunction, which is
characterized by simultaneous presence of decreased lipid lipolysis/oxidation, impaired
adipogenesis and sustained inflammation. Also, there are few dietary approaches or
pharmaceutics that target AT dysfunction for the attenuation of obesity and its related
metabolic complications.
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Given the limitations in the therapeutic approaches for and etiological
knowledge about AT dysfunction in obesity, the purposes of the dissertation are: (1) to
identify potential bioactives that regulate adipose tissue metabolism and inflammation,
(2) to address a potential underlying mechanisms for the development of obesityinduced AT dysfunction and (3) to provide a potential therapeutics against AT
dysfunction. Upon completion of the works, the dissertation would provide scientific
evidence that advance the understanding of pathogenesis of AT dysfunction and can be
utilized for developing therapeutic means against obesity and its related metabolic
complications.

2. Bioactives with Therapeutic Potentials Against AT Dysfunction
2.1. Proanthocyanidin-rich aronia extract mitigates high-fat and high-sucrose
(HF/HS) diet-induced adipose tissue inflammation by inhibiting macrophagic
NF-κB activation
2.1.1. Abstract
Obesity-induced inflammation in adipose tissue (AT) promotes the
development of metabolic dysregulations by increasing macrophage recruitment in the
stromal vascular fraction (SVF). The activation of nuclear factor κB (NF-κB) signaling
in macrophages serves as a pivotal mediator of AT inflammatory responses by
increasing the expression of pro-inflammatory genes in obesity. Given the purported
anti-inflammatory effects of berry consumption in humans, we evaluated if
anthocyanin-rich aronia berry extract (ARN) can prevent obesity-induced AT
inflammation in vivo. We also examined whether ARN suppresses lipopolysaccharide
(LPS)-induced NF-B activation in RAW 264.7 macrophages and mouse bone
marrow-derived macrophages (BMDMs). Male C57BL/6J mice were fed a low-fat diet
(LF), a high-fat and high-sucrose (HF/HS) diet or HF/HS diet supplemented with 0.2%
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ARN (HF/HS+ARN) for 14 weeks. Compared to HF/HS-fed mice, ARN
supplementation tended to decrease fasting serum glucose (p=0.07). Further, ARN
supplementation significantly inhibited the phosphorylation of the NF-B p65 in
epididymal AT with a concomitant decrease in the expression of Cd11b and Tnf
mRNAs in epididymal SVF isolated, compared with those from HF/HS-fed mice.
Consistent with these in vivo findings, ARN-treatment significantly decreased the
phosphorylation of p65 in LPS-stimulated RAW 264.7 macrophages and BMDMs.
Moreover, ARN suppressed LPS-induced mRNA expression of inflammation
mediators (iNos, Cox-2, Tnf, Mcp-1 and Il-6) and glycolysis markers (Glut1, G6pdh
and Hk1) in both cell types. Taken together, our in vivo and in vitro results suggest that
ARN supplementation may attenuate obesity-induced AT inflammation by inhibiting
NF-B signaling and glycolytic pathway in macrophages.

2.1.2. Introduction
Obesity is growing at an alarming rate worldwide and is a significant risk factor
for metabolic disorders including insulin resistance, type 2 diabetes mellitus (T2DM),
dyslipidemia, cardiovascular disease (CVD) and cancer (Ellulu et al., 2017). A body of
evidence suggests that obesity-related inflammation in adipose tissue (AT) underlies
such metabolic abnormalities by increasing inflammatory mediators .(Guilherme,
Virbasius, Puri, & Czech, 2008; Tateya, Kim, & Tamori, 2013) Non-pharmaceutical
interventions such as dietary approaches have shown the potential benefits by
decreasing its proinflammatory milieu (Giugliano, Ceriello, & Esposito, 2006). Thus,
dietary approaches would be an important strategy to manage obesity-mediated
metabolic disorders (Sears & Ricordi, 2011).
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Substantial evidence indicates that obesity-associated AT inflammation is
mainly mediated by accumulation of AT macrophages (ATM) and their subsequent
inflammatory activation (Boutens & Stienstra, 2016). The proliferation of resident
macrophages and recruitment of bone marrow-derived macrophages (BMDMs) in
adipose stromal vascular fraction (SVF) are identified as major sources of and
important mechanisms for AT inflammation in obesity (C. Zheng et al., 2016). (Boutens
& Stienstra, 2016). At the cellular level, it has been shown that the transactivation by
nuclear factor-κB (NF-κB) family members, especially p-65 subunit, is critical for
macrophage survival and inducing pro-inflammatory genes such as monocyte
chemoattractant protein 1 (MCP-1), tumor necrosis factor alpha (TNF), inducible
nitric oxide (iNOS), and cyclooxygenase-2 (Cox-2) (Boutens & Stienstra, 2016; A. A.
Hill et al., 2015; Viatour, Merville, Bours, & Chariot, 2005). A growing number of
recent studies also highlight the critical role of glycolysis and pentose phosphate
pathway for macrophages to not only meet metabolic demands but also support their
functions such as NO production and phagocytosis during the activation of NF-κB
signaling (Lauterbach & Wunderlich, 2017). It has been shown that increased glucose
transport and glycolytic metabolism by glucose transporter 1 (Glut1) and hexokinase 1
(HK1) support macrophage inflammatory responses and function (Freemerman et al.,
2014; Wolf et al., 2016). This indicates that targeting the NF-κB signaling and glucose
metabolism in ATMs could be a potential approach for modifying obesity-induced AT
inflammatory responses and its related metabolic outcomes.
Aronia berry (Aronia Melanocarpa), also known as Chokeberry, is native to the
Northeastern America and was originally used for cold treatment by native Americans.
At present, aronia is a commercial berry crop cultivated in North America and Eastern
European countries (Dubrava, 2015; Strik, Finn, & Wrolstad, 2003). Aronia berry has
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high amounts of polyphenols, and the majority of the compounds are anthocyanin
(Kähkönen, Hopia, & Heinonen, 2001). Clinical studies have shown that aronia berry
consumption reduces fasting blood glucose and lipid in patients with diabetes and
metabolic syndrome (Sikora et al., 2012; Simeonov et al., 2002). Consistently, animal
studies have demonstrated that aronia berry suppresses obesity-induced hyperglycemia
and fatty liver disease (Park et al., 2017; Yamane et al., 2016). However, potential
mechanisms for the beneficial effects of aronia berry consumption on obesity and its
related metabolic health have been incompletely understood. There is a body of
evidence that aronia berry has anti-inflammatory potentials. During lipopolysaccharide
(LPS)-induced inflammation, aronia berry extract prevented macrophage infiltration in
the aqueous humor in mice (Ohgami et al., 2005). In vitro studies have also reported
that aronia berry decreased the expression and secretion of pro-inflammatory cytokines
in RAW 264.7 cells and primary human monocytes (Appel et al., 2015; Macrophages,
Yang, Oh, & Yoo, 2015; Ohgami et al., 2005).
While there is, therefore, evidence for the anti-inflammatory effects of aronia
berry, its underlying mechanisms remain unclear. In the present study, we tested the
hypothesis that aronia berry may prevent obesity-induced AT inflammation and
investigated whether anthocyanin-rich aronia berry extract (ARN) suppresses
inflammatory responses in adipose SVF of mice. We further determined whether the
anti-inflammatory potential of ARN is mediated by suppressing NF-B activation and
glycolytic pathway in RAW 264.7 cells and primary BMDMs.

2.1.3. Materials & Methods
Materials
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Aronia berry extract (ARN, product code 2419800) was generously provided
by Artemis International (Fort Wayne, IN, USA). The ARN was standardized to have
15% anthocyanin and 40% polyphenol content. Dulbecco’s modified Eagle’s medium
(DMEM), Roswell Park Memorial Institute 1640 (RPMI 1640), fetal bovine serum
(FBS), antibiotic-antimycotic solution, and Applied Biosystems® SYBR® Green PCR
Master Mix were purchased from Thermo Fisher Scientific (Waltham, MA, USA). 2Mercaptoethanol and LPS (from E Coli O111:B4) were purchased from Sigma
Chemical Co. (ST Louis, MO, USA).

Cell culture
RAW 264.7 cells (ATCC® TIB-71TM) were cultured in DMEM supplemented
with FBS (10% final concentration) and antibiotic-antimycotic solution (1% final
concentration). 1 x 105 cells/mL was seeded in 6-well plates and incubated overnight.
Then, the cells were serum-starved in serum-free DMEM with antibiotic-antimycotic
solution for 1 hr and subject to ARN-treatment. To obtain BMDMs, femurs and tibias
were harvested from FVB mice at 5 to 6 weeks old, and bone marrow cells were flushed
out and cultured in RPMI 1640 supplemented with 10% FBS, 0.05 μM 2mercaptoethanol and 1% antibiotic-antimycotic solution overnight. Next day, the
floating bone marrow cells were collected, seeded in 6 well plates at the density of 0.2
x 106, and cultured in the medium with M-CSF at 10 ng/mL for 5 days. For treatment,
the both cell types were pretreated with ARN for 1 hr, followed by 12-hr treatment with
ARN in the presence of LPS (100 ng/mL). For western blot analysis, the cells were
treated with ARN and LPS for 1 hr.

Animal experiments
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Male C57BL/6J mice were purchased from the Jackson Laboratory (Bar Harbor,
ME, USA) and housed under a 12 h light/dark cycle. After the acclimation period, mice
were randomly assigned to a low-fat control (LF; 6% fat by wt, n=7), a high-fat/highsucrose control (HF/HS; 34.5% fat, 35% sucrose by wt, n=9), or a HF/HS with ARN
(HF/HS+ARN; 0.2% ARN powder by wt, n=10). The composition of the experimental
diets is listed in Table 1. Mice were allowed ad libitum access to food and water
throughout the 14 weeks of feeding. Body weights and food consumption were
recorded weekly. At the end of the feeding period, mice were fasted for 6 h and
anesthetized by injection of ketamine (110 mg/kg) and xylazine (10 mg/kg) (Henry
Schein Animal Health, Dublin, OH, USA) for euthanization. Blood was collected by
cardiac puncture and centrifuged at 2000 x g for 10 min at 4℃ for serum collection.
Serum and epididymal white adipose tissue samples were stored at -80°C until use. All
animal procedures were approved by the Institutional Animal Care and Use Committee
at the University of Connecticut.
Table 1. Composition of the experimental diets
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Analytical methods for blood biomarkers
Serum glucose levels were measured using a liquid Glucose (Oxidase) reagent
set (Pointe Scientific, Canton, MI, USA). Serum concentration of total cholesterol (TC)
was determined enzymatically using a total cholesterol reagent (Pointe Scientific),
respectively, as previously described (B. Kim et al., 2013).

Isolation of adipocytes and stromal-vascular fractions (AFs and SVFs)
For the isolation of adipocyte and stromal-vascular fractions (AF and SVF), we
combined a portion of collected eWAT from mice per group and had about 2 g in total;
a portion of eWATs from 4 LF-fed mice was combined (n=2), 3 HF/HS-fed mice
combined (n=3), and 3-4 HF/HS+ARN-fed mice combined (n=3). Then, the combined
tissues were rinsed with phosphate buffered saline (PBS, pH 7.4), minced into small
pieces, and digested with PBS containing 2% BSA, collagenase (1 mg/mL final
concentration) and DNase 1 (0.2 mg/mL final concentration) for 20 min at 37°C. Then,
the digested tissues were passed through a mesh and fractionated by brief centrifugation
at 300 g for 5 min. The floating adipocytes under the oil phase were collected as AF,
and the pellets were collected as stromal-vascular fraction. Both fractions were
analyzed with polymerase chain reaction (PCR).

Quantitative real-time-PCR (qRT-PCR)
Total RNAs were isolated using TRIzolTM reagent (Thermo Fisher Scientific)
by following the manufacturer’s protocol, and cDNAs were synthesized using
RevertAid First Strand cDNA synthesis kit (Thermo Fisher Scientific). qRT-PCR was
performed using ViiATM 7 RT-PCR system (Life technologies, Grand Island, NY, USA)
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to analyze the mRNA expression levels of genes. The target genes were normalized by
β-actin or 18S gene expression, and the relative expression was calculated using the 2(ΔΔnd)

. Primers used were mouse-specific and listed in Table 2.

Table 2. The list of primer sequences used

Western blotting
Cell lysates were prepared using RIPA buffer (Thermo Fisher Scientific)
supplemented with a protease and phosphatase inhibitor tablet (Thermo Fisher
Scientific). For Western blot analysis, the same amounts of cell lysates were separated
on 10% SDS polyacrylamide gel, transferred to PVDF membranes, and then incubated
with primary antibody overnight at 4°C, followed by secondary antibody incubation for
1 to 1.5 hr at room temperature. Then, the membrane was exposed to ClairtyTM Western
ECL Blotting substrate (Bio-Rad, Hercules, CA) for 5 min and imaged using an Image
Station 4000MM instrument (Carestream Health, New Haven, CT, USA). The band
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intensities were determined using ImageJ software (U.S. National Institutes of Health,
Bethesda, MD, USA).

Statistics
In vitro data were presented as the means ± S.D, and in vivo data were
expressed as the means ± SEM. The data were analyzed using unpaired t tests, and the
differences were considered statistically significant at P < 0.05.

2.1.4. Results
ARN supplementation decreased serum glucose and total cholesterol (TC) levels, but
did not change body, liver and eWAT weights.
HF/HS and HF/HS+ARN groups showed significantly higher body weight than
LF control group (Fig. 1A). There were no significant differences in food consumption
between HF/HS and HF/HS+ARN groups (data not shown). The liver and eWAT
weights from mice fed HF/HS and HF/HS+ARN were significantly higher than those
from the LF control group, but they were not significantly different from each other
(Fig. 1B). Fasting serum glucose and total cholesterol (TC) levels were significantly
increased in the HF/HS group compared to the LF group, while this increase was
attenuated, albeit not statistically significant, by the HF/HS+ARN group (p=0.07 and
0.17 respectively). (Fig. 1C and D).
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Figure 1. Effect of ARN supplementation on body, liver and eWAT weights and serum fasting glucose and
TC levels in obese mice. Data are expressed as means ± SEM (n = 7 for LF; n = 9 for HF/HS; n = 10 for HF/HS +
ARN). #P<0.05, ##P<0.01, ###P<0.001 as compared to LF gorup.
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ARN supplementation suppressed the phosphorylation of NF-κB p65 subunit in
eWAT and reduced mRNA expression of inflammatory genes in the SVF of eWAT.
The activation of NF-κB signaling, especially disproportionate increases in p65 subunit phosphorylation (p-p65), is a key cellular pathway for macrophage survival
and AT inflammation, leading to metabolic dysregulations in obesity (A. A. Hill et al.,
2015; Viatour et al., 2005). The HF/HS diet greatly increased the phosphorylation of
p65 subunit at Ser536 without altering the total p65 protein levels in eWAT (Fig. 2A).
However, ARN supplementation significantly reduced the expression levels of p-p65
at Ser536, leading to a significant decrease in p-p65 to total p65 ratios.
We next evaluated whether the inhibition of p65 phosphorylation in eWAT by
ARN correlates with the inhibition of macrophage inflammation using SVF isolated
from eWAT of mice fed HF/HS diet. Epididymal SVF isolated from eWAT of the
HF/HS diet-fed mice showed significantly higher mRNA expression levels of
inflammation markers such as Cd11b and Tnfα, than that of LF-fed mice, whereas ARN
supplementation reduced mRNA expression of Cd11b (p=0.055) and Tnfα (p<0.05) in
epididymal SVF when compared to that of the HF/HS diet-fed mice (Fig. 2B). In AF
from eWAT, HF/HS diet suppressed the mRNA expression levels of adipogenic
markers including Pparγ, Adiponectin and Glut4, when compared to LF-fed mice (Fig.
2C). However, no significant changes in the expression of those genes were observed
between HF/HS-fed and HF/HS+ARN-fed groups.
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Figure 2. Effect of ARN supplementation on p-p65 expression at Ser536 in eWAT and macrophage
inflammation (Cd11b & Tnfα) in epididymal SVF. (A) The representative images of protein expression were
shown, and (B) the relative expression was shown in bar graph. (C&D) mRNA expression in SVF. Data are
expressed as means ± SEM (n = 7 for LF; n = 9 for HF/HS; n = 10 for HF/HS with ARN; for data from SVF, n = 2
for LF; n = 3 for HF/HS; n = 3 for HF/HS with ARN). #P<0.05 and ##P<0.01, ###P<0.001 as compared to LF
group. *P<0.05, **P<0.01, and ***P<0.001 as compared to HF/HS group. Cd11b, cluster of differentiation 11b;
Tnfα, tumor necrosis factor alpha; Pparγ, peroxisome proliferator-activated receptor gamma; Glut4, glucose
transporter 4
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ARN-treatment suppressed LPS-induced phosphorylation of p65 subunit in RAW
264.7 macrophages and mouse BMDMs. We further determined whether the
attenuation of AT inflammation in HF/HS+ARN-fed mice is mediated by inhibiting the
NF-κB p65 signaling in macrophages using both RAW 264.7 macrophages and mouse
BMDMs. Cells treated with ARN at the concentrations of 50 and 100 μg/mL showed
no cytotoxic effects on the cells (Ohgami et al., 2005). ARN significantly inhibited
LPS-induced the phosphorylation of p65 at Ser536 without altering total p65 protein
expression in RAW 264.7 macrophages (Fig. 3A) and BMDMs (Fig. 3B). The ratios
of p-p65 to p65 also significantly decreased by ARN in both macrophage cell types,
suggesting that ARN suppresses LPS-induced NF-κB activation in macrophages.
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Figure 3. Effect of ARN on the protein expression levels of p-p65 at Ser536 and p65 in RAW 264.7 cells and
BMDMФs. (A) RAW 264.7 cells. (B) BMDMs. The representative images of protein expression were shown, and
the relative expression was shown in bar graph. Dara are expressed as the means ± SD of three independent
experiments and presented relative to the cells stimulated with LPS only at 100 ng/mL. #P<0.05, ##P<0.01,
###P<0.001 as compared to control (unstimulated cells), *P<0.05, **P<0.01, ***P<0.001 as compared to only LPSstimulated cell.
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ARN-treatment inhibited LPS-induced expression of inflammatory mediators in
RAW 264.7 macrophages and mouse BMDMs. Next, we investigated whether the
inhibition of the NF-κB p-65 phosphorylation by ARN-treatment attenuates the
expression of pro-inflammatory genes in RAW 264.7 macrophages and mouse
BMDMs. ARN-treatment at 50 μg/mL significantly inhibited LPS-induced mRNA
expression of inflammatory mediators including iNos, Cox-2, Tnfα, Mcp-1 and Il-6) in
RAW 264.7 macrophages (Fig. 4 A and B) and BMDMs (Fig. 4 D and E). No further
inhibitions were observed at 100 μg/mL compared to 50 μg/mL. In addition, LPS
stimulation in both cell types markedly increased mRNA expression of genes involved
in glycolysis (Glut1 and hexokinase 1, Hk1) and pentose phosphate pathway (glucose6-phosphate dehydrogenase, G6pdh) (Fig. 4 C and F), a key feature required for
inflammatory functions of macrophages (Lauterbach & Wunderlich, 2017). ARNtreatment, however, significantly inhibited LPS-induced upregulation of these
glycolytic genes.
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Figure 4. Effect of ARN on inflammatory mediators, inflammatory cytokine expression and glycolysis in
RAW 264.7 cells and primary BMDMФs. (A-C) RAW 264.7 cells. (D-F) BMDMФs. Dara are expressed as the
means ± SD of three independent experiments and presented relative to the cells stimulated with LPS only at 100
ng/mL. #P<0.05, ##P<0.01, ###P<0.001 as compared to control (unstimulated cells), *P<0.05, **P<0.01,
***P<0.001 as compared to only LPS-stimulated cell. iNos, inducible nitric oxide synthase; Cox2, cyclooxygenase
2; Tnfα, tumor necrosis factor alpha; Mcp-1, monocyte chemoattractant protein-1; Il-6, interleukin 6; Glut1,
glucose transporter 1; G6pdh, glucose-6-phosphate dehydrogenase; Hk1, hexokinase 1
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2.1.5. Discussion
AT inflammation is a significant characteristic of obesity and promotes the
development of metabolic dysregulations such as hyperglycemia and hyperlipidemia
(Guilherme et al., 2008; Tateya et al., 2013). A growing body of evidence suggests that
the consumption of aronia berries may prevent obesity-related metabolic disorders in
humans, including hyperglycemia and hyperlipidemia (Sikora et al., 2012; Simeonov
et al., 2002). However, its target tissue(s) and underlying mechanism(s) have been
incompletely understood, limiting the potential application of aronia berry as functional
ingredients. Particularly, very few studies have documented the anti-inflammatory
mechanisms of aronia berry in regard to obesity-induced AT inflammation and NF-κB
signaling, a critical cellular pathway that regulates macrophage activation and
inflammatory responses (Appel et al., 2015; A. A. Hill et al., 2015; Ohgami et al., 2005).
In the present study, we found that ARN supplementation decreased macrophage
inflammation in eWAT and its SVF from the HF/HS-fed mice with a concomitant
decrease in the phosphorylation of NF-κB p65 at Ser536 and also in the expression of
Cd11b and Tnfα mRNAs. Zheng et. al. reported that CD11b deficiency prevented
obesity-induced insulin resistance in mice (Chunxing Zheng et al., 2015). Moreover,
TNFα deficiency protects obesity-induced ATM accumulation and insulin resistance in
mice (Bouter et al., 2010; De Taeye et al., 2007). Thus, our data indicate that ARN
supplementation may mediate its beneficial effects on obesity-induced metabolic
dysregulations by targeting ATM accumulation and inflammation.
To gain insight into molecular mechanisms for the anti-inflammatory effect of
ARN in AT inflammation, we performed in vitro studies using two different
macrophage cell types, RAW 264.7 macrophages and mouse BMDMs, which represent
macrophages in adipose SVF. We focused on the phosphorylation of the NF-κB p65,
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which precedes the transactivation for genes responsible for inflammation and
glycolytic pathway in macrophages (Lauterbach & Wunderlich, 2017). We found the
inhibitory

effects

of

ARN

supplementation

on

HF/HS

diet-induced

p65

phosphorylation in eWAT with concomitant decreases in inflammatory markers in
epididymal SVF. Consistent with the in vivo results, ARN-treatment significantly
inhibited the phosphorylation of p65 and its target gene expression in both cell types
during LPS stimulation. Recent studies have suggested that targeting either circulating
proinflammatory cytokines or NF-κB signaling pathways in macrophages is a viable
therapeutic approach to inhibit ATM inflammation especially in obesogenic
environment (A. A. Hill et al., 2015; Panee, 2012). We also found that ARN-treatment
resulted in a significant inhibition of glycolytic genes such as Glut1, G6pdh, and Hk1,
all of which were evidently increased by LPS stimulation. In recent years, the
upregulation of glycolytic and pentose phosphate pathways has been identified as an
important metabolic feature of activated macrophages in regulating inflammatory
responses (O’Neill, Kishton, & Rathmell, 2016) Thus, ARN treatment may target p65specific transactivation and/or glucose metabolism that could be a potential
mechanisms to exert its anti-inflammatory effects in macrophages.

Previous in vivo studies have shown that aronia berries improved obesityinduced hepatic lipid accumulation and hyperglycemia (Park et al., 2017; Yamane et
al., 2016). Recent clinical trials have also reported that aronia berries exerted the
beneficial effects on obesity-related hyperlipidemia and hyperglycemia (Sikora et al.,
2012; Simeonov et al., 2002; Yamane et al., 2017). Yamane, et al (Yamane et al., 2016)
demonstrated that aronia berry juice inhibited α-glucosidase activity in the upper region
of the small intestine. In addition, Park, et al (Park et al., 2017) reported that aronia
extract inhibited hepatic PPARγ expression to attenuate TG accumulation and oxidative
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stress in obese mice. In contrast to other reports, we observed no statistically significant
effects on blood glucose and TC levels by ARN supplementation in vivo. The
discrepancy related to aronia berry effects on obesity-induced metabolic dysregulations
could be due to several factors including a type of diet, the amount of berry
supplemented, or polyphenolic composition in the berries (Baum, Howard, Prior, &
Lee, 2016). It could be also attributable, in part, to our HF/HS diet-induced obesity
model, which represents mild obesity with an average of 1.3-fold increase of tissue
weights compared to LF-fed mice. In general, the feeding of a HF/HS diet for 14 weeks
induces at least 1.5- to 2-fold increase in tissue weights and more than 2-fold increase
in plasma metabolic markers, compared to lean counterpart (Ishimoto et al., 2013; Oishi
et al., 2015; Sato et al., 2010). Therefore, this also suggests a less pronounced severity
of obesity developed in our diet-induced obesity model as another potential factor for
the different results from other studies.
In conclusion, our findings demonstrated that ARN supplementation
ameliorates obesity-induced ATM inflammation, mainly through the suppression of
NF-κB activation and glycolytic pathway with significant decreases in the expression
of inflammatory mediators in vitro and in vivo. The present study suggests that ARN
could serve as a dietary means to attenuate obesity-induced inflammation in AT.
However, further research is needed to determine effective doses of aronia berry extract.
Also, testing the role of aronia berry using a severe obesity model is required to better
define its health benefits in obesity-related chronic diseases.
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2.2. Mechanism of formononetin-induced adipocyte fatty acid oxidation and
preadipocyte differentiation
2.2.1. Abstract
Decreased adipocyte fatty acid oxidation (FAO) and impaired preadipocyte
differentiation characterize hypertrophic expansion of adipose tissue (AT) from obese
and insulin resistant humans and are recognized as potential mechanisms for obesitymediated dyslipidemia. Supplementation of formononetin (FMN), one of the principal
isoflavones extracted from red clover or Huangqi (Astragalus roots), has been shown
to have beneficial effects on obesity-related hyperlipidemia, a well-established
cardiovascular risk factor. However, a target tissue and underlying mechanism(s)
through which FMN acts have been under-investigated. Thus, we investigated whether
FMN promotes adipocyte FAO and preadipocyte differentiation using 3T3-L1
preadipocytes to provide potential mechanisms of FMN action. We further extended
this to the culture of 10T1/2 mesenchymal stem cells (MSCs) as well as mouse AT
explants to reflect in vivo effects of FMN. In fully differentiated 3T3-L1 adipocytes,
FMN-treatment significantly increased the expression levels of FAO-related proteins
such as pAMPK, pACC, and CPT1, all of which were consistently upregulated in AT
explant cultures treated with 10 μM FMN. In addition, FMN significantly enhanced the
degree of differentiation of both 3T3-L1 preadipocytes and 10T1/2 MSCs into
adipocytes as evidenced by Oil Red O staining of cellular lipids. This observation
correlated with increased expression levels of key adipogenic transcription factors
(PPARγ and C/EBPα) and their down-stream target proteins (FABP4, Glut4 and
adiponectin). Moreover, FMN failed to exert its stimulatory effects on preadipocyte
differentiation in both cell types in the presence of a PPARγ antagonist, suggesting a
PPARγ-dependent effect of FMN. Collectively, these data provide possible
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mechanisms of action of FMN on lipid metabolism and further support the favorable in
vivo effects of FMN in diet and obesity-induced dyslipidemia.
2.2.2. Introduction
Adipose tissue (AT) serves as an energy reservoir and plays a critical role in the
whole-body metabolic homeostasis by regulating glucose and lipid metabolism
(Cignarelli et al., 2019). Dysregulated lipid metabolism in AT contributes to ectopic fat
accumulation in peripheral tissues and hyperlipidemia (i.e., elevated levels of blood
lipids and free fatty acids), which are strong risk factors for the development of
metabolic and cardiovascular disease in obese individuals (Bays et al., 2013). In
humans, adipose mass expands by enlarging the size of pre-existing adipocytes
(hypertrophy) and/or by increasing the number of new adipocytes (hyperplasia) through
the recruitment and differentiation of precursor cells (Cignarelli et al., 2019). Recent
evidence suggests that hypertrophic obesity is strongly associated with obesitymediated metabolic complications such as insulin resistance and type 2 diabetes (T2D),
while hyperplastic obesity is less likely linked to these metabolic consequences (Marini
et al., 2007; Stefan et al., 2008). Moreover, the rates of new fat cell generation were
significantly reduced in obesity and inversely associated with body mass index (BMI)
and adipocyte cell size of the donors, which correlated with decreased expression of the
differentiation marker genes including peroxisome proliferator-activated receptor
(PPARγ), glucose transporter 4 (GLUT4) and adiponectin (Isakson, Hammarstedt,
Gustafson, & Smith, 2009b; Martínez-Jiménez et al., 2019). Thus, an important
consequence of impaired adipocyte differentiation is the pathological hypertrophic
expansion of AT that has been linked to obesity-induced adipose dysfunction and
hyperlipidemia (Frayn et al., 2012; Rydén et al., 2013).
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Mesenchymal stem cells (MSCs) are a major source of new adipocyte
generation through the commitment into preadipocytes, followed by terminal
differentiation to mature adipocytes (Cignarelli et al., 2019). The adipogenic program
is tightly regulated by a coordinated interplay of key transcription factors such as
PPARγ and CCAAT/enhancer-binding protein alpha (C/EBPα) that control the
downstream target genes such as fatty acid-binding protein 4 (FABP4), GLUT4 and
adiponectin, thereby acquiring phenotypic functions of adipocytes (Ntambi & YoungCheul, 2000). In particular, PPARγ is a critical regulator of adipocyte differentiation
and a nuclear receptor for anti-diabetic drugs, thiazolidinediones (TZDs) that are shown
to be effective in lowering hyperlipidemia and thus reducing cardiovascular risks in
diabetic patients (Haberbosch, 2007). An increasing body of evidence in animals and
humans also suggests that hypertrophic obesity is closely associated with reduced
mitochondrial fatty acid oxidation (FAO) with a significant decrease in AT lipid
turnover (Choo et al., 2006; Frayn et al., 2012; Goossens & Blaak, 2015; J. I. Kim et
al., 2015; Schöttl, Kappler, Fromme, & Klingenspor, 2015). A central player in the
regulation of mitochondrial FAO is AMP-activated protein kinase (AMPK), a cellular
energy censor, which is known to regulate carnitine palmitoyl transferase 1 (CPT1),
acetyl-CoA carboxylase (ACC) and adiponectin, all of which are reduced in obesity
(Lihn, Jessen, Pedersen, Lund, & Richelsen, 2004; Mottillo et al., 2016). Although the
underlying mechanism for the development of abnormal lipid metabolism in obese AT
is still unclear, it has been demonstrated that decreased adipocyte lipid oxidation and/or
new fat cell formation in AT results in hyperlipidemia in humans (P. Arner et al., 2011;
Frayn et al., 2012; Isakson et al., 2009b; Rydén et al., 2013). Therefore, agents that
promote adipocyte FAO and/or preadipocyte differentiation would not only prevent

31

hypertrophic expansion of adipocytes, but also be a promising strategy for managing
and preventing lipid abnormalities in obesity and thus cardiovascular risk.
Formononetin (FMN) is one of the principal isoflavones found in red clover and
Huangqi (Astragalus roots). A recent randomized controlled trial has reported that
FMN-enriched red clover extract improved hyperlipidemia in menopause women
(Clifton-Bligh et al., 2015). Consistently, in mice, FMN supplementation has been
shown to significantly attenuate diet-induced obesity and hyperlipidemia (Gautam et
al., 2017). As a potential mechanism, Gautam et. al. (Gautam et al., 2017) suggested
that FMN may increase energy expenditure in obese mice, but potential target tissues
and underlying mechanisms have not been identified. Also, in vitro studies using 3T3L1 cells, a well-characterized immortalized preadipocyte cell line, have generated
contrasting results about the effects of FMN on preadipocyte differentiation; a
stimulatory effect on adipogenesis at 5 to 50 μM (Andersen et al., 2014) and an
inhibitory effect at 100 pm to 1 μM (Gautam et al., 2017). Therefore, a limited and
inconsistent evidence hardly explains a possible mechanism of action by which FMN
attenuates obesity-mediated hyperlipidemia.
The aim of this study was to investigate the effects of FMN on adipocyte lipid
oxidation and preadipocyte differentiation using 3T3-L1 preadipocytes. Potential
effects on this well-established cell line were further confirmed using the culture of
mouse epididymal white AT (eWAT) explants and 10T1/2 multipotent MSCs to gain
insight into the mode of action of FMN at AT level. Because of the contrasting
observations on the effects of FMN on 3T3-L1 preadipocyte differentiation, we used a
range of FMN concentrations (1 to 20 μM), which are within a physiologically
achievable concentration range in mice (Luo et al., 2018) .
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2.2.3. Materials & Methods
Materials
Bisphenol A diglycidyl ether (BADGE), GW9662, insulin from bovine
pancreas, 3-isobutyl-1-methylxanthine (MIX), and dexamethasone were purchased
from Sigma-Aldrich (St. Louis, MO, USA). Cell culture reagents including Dulbecco’s
modified Eagle’s medium (high glucose, DMEM), DMEM/F12 medium, newborn calf
serum (NCS), fetal bovine serum (FBS), and penicillin/streptomycin were purchased
from

Invitrogen

(Carlsbad,

CA,

USA).

Formononetin

(7-hydroxy-4’-

methoxyisoflavone), anti-PPARγ, anti-C/EBPα, anti-CPT-1A, anti-GLUT4 and HRPconjugated β-actin antibodies were purchased from Santa Cruz Biotechnology (Santa
Cruz, CA, USA). anti-pAMPK, anti-pACC, anti-AMPK, anti-ACC, anti-FABP4 and
anti-adiponectin antibodies were obtained from Cell Signaling Technology (Danvers,
MA, USA).

Cell Culture and Treatment
3T3-L1 preadipocytes were maintained in DMEM containing 10% NCS, 100
unit/mL penicillin, and 50 μg/mL streptomycin at 37°C under 5% CO2 atmosphere. To
induce differentiation of preadipocytes into adipocytes, post-confluent cells (designated
Day 0) were cultured in a differentiation medium (DMEM media containing 10% FBS,
167 nM insulin, 0.5 mM MIX, and 1 μM dexamethasone). The cell culture medium was
changed with 10% FBS-DMEM containing 167 nM insulin 2 days after and refreshed
every other day until day 6. Differentiated adipocytes were subjected to Oil Red O
staining and harvested for protein analysis. C3H10T1/2 cells (10T1/2 cells) were
maintained in phenol red free-DMEM/F12 media. Upon reaching confluence (Day 0),
cells were induced to differentiate in 5% FBS-DMEM/F12 supplemented with 167 nM
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insulin, 0.5 mM MIX, and 1 μM dexamethasone for 2 days. Cells were then incubated
in DMEM/F12 containing 5% FBS and 167 nM insulin until day 8 to 10. Differentiated
adipocytes were subjected to Oil Red O staining and harvested for protein analysis.
Formononetin (FMN) was reconstituted as 100 mM stock solutions in DMSO (dimethyl
sulfoxide) and added from the indicated concentrations on Day 0.

Oil Red O staining
To measure the degree of differentiation of preadipocytes into adipocyte, Oil
Red O staining was performed. Cells were washed twice with phosphate-buffered saline
(PBS, pH 7.4), fixed in 10% formalin for 20 min at room temperature (RT), and then
washed with PBS twice. Lipid droplets in the cells were stained with 0.3% Oil Red O
solution at RT for 20 minutes and completely washed out with distilled water. After
drying exhaustively, stained Oil Red O formazan was eluted with 100% isopropanol
and quantified at 490 nm.

Explant Culture of Epididymal White Adipose Tissue (eWAT)
Epididymal white adipose tissue (eWAT) was obtained from FVB male mice
aged 6 weeks (n=2) and was subject to explant culture. Briefly, 100 mg of tissues was
cut in small pieces under laminar airflow and sterile conditions and placed on a 6-well
plate in 10% FBS-DMEM at 37°C under 5% CO2 atmosphere for 3 hours for relaxation.
Then, the media were refreshed and cultured in the presence or absence of FMN (10
μM) for 3 hours by shaking at 70 rpm and harvested for protein analysis.

Western blot
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Cells and explants were lysed in RIPA extraction buffer [25mM Tris-HCl (pH
7.6), 150mM NaCl, 1% NP-40, 1% sodium deoxycholate, and 0.1% SDS] containing
both protease and phosphatase inhibitors (Roche, Indianapolis, IN, USA). The protein
concentration of each sample was determined using BCA protein assay reagent (Pierce,
Rockford, IL, USA). Twenty micrograms of protein were separated on 8–12% SDSpolyacrylamide gels, followed by electrophoretic transfer to a nitrocellulose membrane.
Primary antibodies were incubated overnight at 4°C at a 1:2000 dilution. After
incubating with the secondary antibody at room temperature for 2 h, the proteins were
detected using the ECL western blotting analysis system (Pierce). Each protein
expression was normalized to β-actin.

Statistical analysis
All data are obtained from at least three independent experiments except for
explant culture of eWAT (n=2) and represented as means ± S.D. Statistical analysis
was carried out by SAS version 9.1 (SAS Institute, Cary, NC). Significant differences
were accepted at the significant level of 0.05 with one-way analysis of variance
(ANOVA) followed by Duncan’s multiple range test.
2.2.4. Results
FMN increases CPT-1 expression and ACC phosphorylation through AMPK
phosphorylation in fully differentiated 3T3-L1 adipocytes.
The activation of AMPK through the phosphorylation of AMPK on Thr172 is
known to increase the expression of CPT1 and mitochondrial FAO (Osler & Zierath,
2008). Activated pAMPK phosphorylates and inactivates ACC, lowering malonyl-CoA
levels and, thus, promoting CPT1-mediated mitochondrial FAO while suppressing fatty
acid synthesis (Galic et al., 2018). Given the importance of adipocyte fatty acid
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metabolism, we first determined whether FMN increases FAO through AMPK
phosphorylation in mature adipocytes. As shown in Fig. 5, FMN significantly increased
the phosphorylation of AMPK and ACC with their expression levels peaked at 5 μM
and plateaued up to 20 μM in fully differentiated 3T3-L1 adipocytes compared with
control cells (Fig. 5 A). However, no significant differences in total AMPK and ACC
levels by FMN at all concentrations used were observed compared to the control cells
(Fig. 5 B). FMN also markedly increased the expression of CPT1 protein with the
highest expression level observed at 10 μM concentration.
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Figure 5. FMN increases AMPK-mediated lipid oxidation in in vitro 3T3-L1. (A) Representative image of
protein expression in 3T3-L1 adipocytes (n=4). (B) Different letters in the bar graph indicate statistically significant
difference at the level of 0.05.
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FMN consistently increases pAMPK, pACC, and CPT-1 in mouse eWAT explant
culture.
Next, we extended our question to determine whether the in vitro findings are
replicable at the AT level. To address this, fresh mouse eWAT explants were cultured
with or without FMN at 10 μM concentration that showed the highest effect on CPT1
expression in 3T3-L1 adipocytes (Fig. 5). Consistent with the observations in
differentiated 3T3-L1 adipocytes, FMN at 10 μM greatly increased the expression
levels of pAMPK and pACC in eWAT explants compared to non-treated ones (Fig. 6).
We also found a concomitant increase in the expression levels of CPT1 in the tissues.
Collectively, our in vitro and ex vivo findings indicate that FMN increases FAO through
AMPK phosphorylation in AT.
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Figure 6. FMN increases phosphorylations of AMPK and ACC and CPT1 expression in mouse epididymal
white adipose tissue (eWAT) explants. (A) The expression of proteins in eWAT and (B) bar graph (n=2).
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FMN stimulates differentiation of 3T3-L1 preadipocytes into adipocytes via PPARγ
activation.
In addition to adipocyte lipid oxidation, the effects of FMN on preadipocyte
differentiation were investigated using 3T3-L1 preadipocytes. As shown in Fig. 7,
when compared to non-treated cells, FMN promoted lipid accumulation during 3T3-L1
preadipocyte differentiation as measured by ORO staining with the greatest abundance
of lipid droplets at 20 μM. FMN treatment also significantly upregulated the protein
expression levels of differentiation-related key transcription factors such as PPARγ and
C/EBPα as well as adipocyte-specific genes including FABP4, GLUT4, and
adiponectin (Fig. 7 B). The upregulation of the expression of these proteins reached the
highest level at 20 μM, suggesting that FMN enhances the formation of new adipocytes
through adipogenic program.
Next, we questioned whether the stimulatory effect of FMN on the
differentiation of 3T3-L1 preadipocytes was dependent on PPARγ, a master regulator
of preadipocyte differentiation. The co-treatment of FMN with a PPARγ antagonist,
BADGE significantly reduced ORO staining of lipids compared to the cells treated with
only FMN (Fig. 7 C). We also found that BADGE co-treatment significantly decreased
the expression of PPARγ, adiponectin and FABP4 proteins, suggesting that FMN
promotes adipocyte differentiation via PPARγ activation.
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Figure 7. FMN enhances differentiation of 3T3-L1, and its stimulatory effect was blocked in the presence of
a PPARγ antagonist. (A & B) 3T3-L1 preadipocytes were differentiated in the presence or absence of FMN at the
indicated concentrates (n=3). (C & D) 3T3-L1 preadipocytes were co-treated with FMN and BADGE during its
differentiation into adipocytes. Representative image of Oil Red O staining and protein expression in 3T3-L1
preadipocytes were presented (n=3). Different letters indicate statistically significant difference at the level of 0.05.
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A PPARγ antagonist inhibits FMN-mediated adipocyte differentiation in 10T1/2
MSCs.
It is well-established that a mouse embryos-derived 10T1/2 cell line is
functionally similar to and pluripotent as in vivo adipose progenitor cells, MSCs (Tang,
Otto, & Lane, 2004). Because these MSCs are important variables that influence the
overall adipose cellularity, we investigated the effects of FMN on the degree of
differentiation using 10T1/2 MSCs (Fig. 8). Consistent with the observations in 3T3L1 preadipocytes, FMN treatment substantially increased lipid accumulation during
10T1/2 MSC differentiation with the greatest abundance of ORO-stained lipid droplets
observed at 20 μM compared to non-treated cells (Fig. 8 A). We also found that the
protein expression levels of PPARγ, C/EBPα, FABP4, GLUT4 and adiponectin were
significantly enhanced in the presence of FMN, reaching the highest levels at 20 μM
(Fig. 8 B). Moreover, 10T1/1 MSCs co-treated with FMN and GW9662 (PPARγ
antagonist) significantly reduced the abundance of ORO-stained lipid droplets and
levels of PPARγ protein when compared to FMN-treated cells (Fig. 8 C & D),
suggesting that the stimulatory effects of FMN on 10T1/2 MSCs differentiation into
adipocyte are PPARγ-dependent as observed in 3T3-L1 preadipocytes.
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Figure 8. FMN promotes 10T1/2 MSC differentiation into adipocytes via PPARγ. (A & B) 10T1/2 MSCs were
differentiated in the presence or absence of FMN at the indicated concentrates (n=3). (C & D) 10T1/2 MSCs were
co-treated with FMN and GW9662 during its differentiation into adipocytes. Representative image of Oil Red O
staining and protein expression in 10T1/2 MSCs were presented (n=3). Different letters indicate statistically
significant difference at the level of 0.05.
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2.2.5. Discussion

Obesity-induced abnormalities in lipid metabolism in AT contribute to the
development of hyperlipidemia which is a strong risk factor for metabolic and
cardiovascular diseases (Bays et al., 2013). A line of evidence suggests that decreased
fat cell turnover through preadipocyte differentiation and/or reduced adipocyte lipid
oxidation in obese humans characterize obesity-mediated metabolic abnormalities,
particularly the development of dyslipidemia and ectopic fat accumulation (Frayn et al.,
2012; Rydén et al., 2013; Spalding et al., 2008). It has been reported that FMN, a major
isoflavone abundantly found in red clover and Huangqi (Astragalus roots), has blood
lipid-lowering potentials in menopausal women and obese mice (Clifton-Bligh et al.,
2015; Gautam et al., 2017). However, potential target tissues and mechanisms
responsible have been still unknown. In this study, we demonstrated that FMN can
promote adipocyte lipid oxidation through AMPK phosphorylation and also enhance
preadipocyte differentiation via PPARγ activation using 3T3-L1 preadipocyte cell line.
Our consistent findings using the culture of mouse eWAT explants and 10T1/2 MSCs
further support the dual mode of biological action of FMN at the AT level. Thus, our
data indicate that FMN-enriched diets or supplements may reduce the risk for
hyperlipidemia and its related cardiovascular outcomes by promoting preadipocyte
differentiation and adipocyte lipid oxidation in AT in obesity.
Preadipocyte differentiation involves the recruitment of MSCs that undergo
commitment

and

differentiation

into

preadipocytes,

followed

by

terminal

differentiation into adipocytes (Cignarelli et al., 2019). There is a continuous turnover
of fat cells in humans through preadipocyte differentiation with approximately 10 %
per year (Spalding et al., 2008). Moreover, recent studies demonstrated that the rates of
preadipocyte differentiation are reduced in obese and diabetic humans and inversely
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correlated to existing adipocyte size and BMI (Isakson et al., 2009b; Martínez-Jiménez
et al., 2019). The transcription factor PPARγ is well-known as a master regulator of
preadipocyte differentiation and metabolism as evidenced by the demonstration that
PPARγ overexpression was sufficient to trans-differentiate non-adipocytes into
adipocyte-like cells (Siersbæk, Nielsen, & Mandrup, 2010). In addition to the critical
role of PPARγ in regulating preadipocyte differentiation, PPARγ expression in AT was
reduced in obese and diabetic humans with low preadipocyte differentiation capacity,
adipocyte hypertrophy, and metabolic dysregulation (Isakson et al., 2009b; Lessard et
al., 2014; Martínez-Jiménez et al., 2019). However, the synthetic ligands of PPARγ,
TZDs, significantly improved lipid dysregulation and insulin sensitivity in obese
diabetic subjects (Haberbosch, 2007; Ranganathan et al., 2006), supporting the notion
that reduced PPARγ expression and a limited ability to expand AT by differentiating
precursor cells lead to increased lipid levels in the blood and non-adipose cells.
A growing body of evidence in humans and animals has indicated the potential
blood lipid-lowering effects of FMN (Clifton-Bligh et al., 2015; Gautam et al., 2017).
Shen et al (Shen, Liu, Ng, Chan, & Yong, 2006) reported that FMN along with soy
isoflavones, such as daidzein and genistein, is a potential PPAR agonist, with consistent
observations that 3T3-L1 preadipocyte differentiation was significantly enhanced by
FMN treatment at 5 to 50 μM (Andersen et al., 2014). However, in contrast to the
previous reports, recent in vitro data by Gautam et al (Gautam et al., 2017) showed that
FMN suppressed 3T3-L1 preadipocyte differentiation by suppressing PPARγ
expression at 100 pm to 1 μM. These conflicting results obtained from different studies
could be mainly attributable to the differences in the concentrations of FMN.
Considering pharmacokinetic analysis in mice showing that 4 mg/kg intravenous
injection resulted in approximately 1.3 μM in 30 minutes (Luo et al., 2018), we used
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the range of concentrations (1 to 20 μM) that are physiologically relevant and
achievable through dietary means. In contrast to Gautam et al (Gautam et al., 2017),
our data showed that FMN promoted 3T3-L1 preadipocyte differentiation with the
comparable effects on 10T1/2 MSCs at the concentration range from 1 to 20 μM. The
co-treatment of FMN with PPARγ antagonists further indicates that the stimulatory
effect of FMN on 3T3-L1 and 10T1/2 cells was PPARγ-dependent, consistent with the
finding by Shen et al (Shen et al., 2006). Therefore, our results suggest that FMN
enhances preadipocyte differentiation by targeting PPARγ, which could be a possible
mechanism by which FMN exerts blood lipid-lowering effects in humans and animals.
An important outcome of impaired formation of new fat cells through adipocyte
differentiation is the pathological expansion of hypertrophic adipocytes that is closely
linked to metabolic complications such as insulin resistance and dyslipidemia (Frayn et
al., 2012; Rydén et al., 2013). When compared to lean adipocytes, hypertrophied
adipocytes exhibit decreased lipid and glucose sequestration, reduced lipid hydrolysis
and oxidation that correlated closely to hyperlipidemia in obese humans (Frayn et al.,
2012; Goossens & Blaak, 2015; J. I. Kim et al., 2015). Gautam et al (Gautam et al.,
2017) have shown that the blood lipid-lowering effects of FMN supplementation in
obese mice were attributable to increased thermogenesis based on the increased mRNA
levels of uncoupling protein 1 (UCP1) in eWAT. In addition to the pivotal role of UCP1
in the regulation of thermogenesis in brown adipocytes, white adipocyte UCP1
functions as a futile substrate cycle to control mitochondrial FAO via the activation of
AMPK, which is a sensor of cellular energy status (Flachs, Rossmeisl, Kuda, &
Kopecky, 2013). Thus, this led us to hypothesize that FMN may increase AMPKdependent FAO in adipocytes. The present study is, to the best of our knowledge, the
first work showing that FMN promotes AMPK phosphorylation in adipocytes. In
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addition, FMN significantly increased expression levels of key proteins involved in
FAO, such as pAMPK, pACC, and CPT-1. Furthermore, we confirmed the potential
effects of FMN on lipid oxidation in AT using mouse eWAT explant culture as
supported by the consistent upregulation of pAMPK, pACC and CPT-1 proteins.
In conclusion, FMN is one of the widely used bioactive constituents, and both
FMN research and market demands have substantially increased in the past decades.
Our in vitro and ex vivo data provide additional information for a potential target tissue
and molecular mechanisms by which FMN increases AT energy expenditure that may
account for its blood lipid-lowering effects observed in previous in vivo studies
(Gautam et al., 2017). We further showed that FMN increased lipid oxidation in
adipocytes through AMPK-ACC-CPT1 pathway and stimulated preadipocyte
differentiation via PPARγ activation. Although our data suggest that FMN
supplementation may attenuate obesity-induced dyslipidemia by targeting AT lipid
metabolism, further studies are needed to determine the in vivo effects of dietary FMN
using pre-clinical and/or clinical models.
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2.3. Anti-inflammatory effects of proanthocyanidin-rich cranberry extract
through the suppression of NF-kB pathway and histone acetylase in RAW
264.7 and mouse bone marrow-derived macrophages

2.3.1. Abstract
Obesity-mediated chronic inflammation promotes the progression of obesity to
metabolic anti-inflammatory effect of cranberries by decreasing plasma inflammatory
cytokines. However, its specific mechanisms of action remain unclear. The nuclear
factor-κB (NF-κB) pathway in macrophages plays a critical role in regulating the
expression of many inflammatory genes, and histone acetylation has been identified as
a key epigenetic modification for the NF-κB p65-mediated inflammatory responses.
We investigated if proanthocyanidin (PAC)-rich cranberry extract (CBE) suppresses
histone acetylation and NF-κB p65 activation in RAW 264.7 macrophages and mouse
bone marrow-derived macrophages (BMDMs). Treatment with 5% and 15% PACcontaining CBEs markedly suppressed the expression of pro-inflammatory mediators
(iNos, Cox-2, Tnfα, Mcp-1 and Il-6) in both RAW 264.7 macrophages and BMDMs
stimulated with lipopolysaccharides (LPS). CBE significantly reduced LPS-induced
phosphorylation of p65 in both cell types without changing total p65 expression levels.
Moreover, 15% PAC-CBE increased the expression levels of histone deacetylase 3
(HDAC3) with a concomitant decrease in histone H4 acetylation levels. These results
suggest that CBE increases HDAC3 protein expression with the subsequent inhibition
of p65 phosphorylation to mediate anti-inflammatory effects in macrophages.
Cranberries may serve as a dietary agent to attenuate chronic inflammation in patients
with obesity and related complications.
2.3.2. Introduction
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Chronic inflammation has been recognized as an important mediator for the
progression of obesity to metabolic disorders such as insulin resistance, type 2 diabetes
mellitus (T2DM) and cardiovascular disease (CVD) (Bonaccio et al., 2016; Wynn &
Vannella, 2016; Zheng et al., 2016). Obesity-induced inflammation is primarily
mediated by the accumulation of macrophages in adipose tissue (AT), which are mainly
originated from bone marrow-derived macrophages (BMDMs) (Zhao, Zou, Du, & Zhao,
2018; Zheng et al., 2016). The recruitment and subsequent activation of BMDMs are a
prominent source of pro-inflammatory cytokines that serve as a potential link between
obesity and metabolic diseases (Zhao et al., 2018; Zheng et al., 2016). Consistently,
specific deletion of AT macrophages showed a striking loss of gene markers for
macrophages and inflammation with improved dyslipidemia and insulin resistance in
diet-induced obese mice (Bu, Gao, Qu, & Liu, 2013). Although anti-inflammatory
agents such as nonsteroidal anti-inflammatory drugs (NSAIDs) are commercially
available, clinical trials have raised safety concerns due to adverse effects related to the
use of these drugs (Gislason et al., 2009; Lee, Bartle, & Weiss, 2007). Increased
consumption of certain fruits and vegetables rich in polyphenols has been shown to be
safe and effective for managing chronic inflammatory conditions (Amiot, Riva, &
Vinet, 2016). Thus, identifying food sources and bioactives with anti-inflammatory
properties and potential mechanisms involved would be an important strategy to
develop dietary interventions to prevent or treat obesity-related chronic inflammation
and metabolic disorders.
The activation of nuclear factor-kappa B (NF-κB) signaling is a key molecular
mechanism for inflammatory responses by inducing the expression of various proinflammatory genes such as inducible nitric oxide synthase (iNOS), tumor necrosis
factor alpha (TNFα), monocyte chemoattractant protein-1 (MCP-1) in macrophages

49

(Natarajan, Abraham, Kota, & Isaac, 2018). There are five proteins that compose NFκB family, such as p65 (Rel-A), Rel-B, c-Rel, p50, and p52 (Giridharan & Srinivasan,
2018). The NF-κB p65 subunit has gained considerable attention as a major target
protein for drug discovery to tackle chronic inflammation because of the
disproportionate increase of p65-mediated transactivation of pro-inflammatory genes
in obesity-linked metabolic diseases (Giridharan & Srinivasan, 2018). To induce proinflammatory genes, the NF-κB p65 is phosphorylated and translocated into the nucleus,
followed by histone acetylation on the promoter regions of its target genes, which are
constrained by histone deacetylation. This in turn allows p-p65 to bind to its specific
element, regulating the expression of pro-inflammatory genes (Barish et al., 2010;
Viatour, Merville, Bours, & Chariot, 2005). Among histone deacetylases (HDACs),
HDAC 3 has been identified as a key regulator of histone deacetylation at inflammatory
gene enhancers (Barish et al., 2010). Therefore, suppressing p65 phosphorylation
and/or interrupting histone acetylation during NF-κB activation would be a promising
molecular target for preventing macrophage-induced inflammation in obesity and its
related metabolic complications (Leus, Zwinderman, & Dekker, 2016).
Cranberries (Vaccinium macrocarpon) are indigenous to North America and are
high in micronutrients and polyphenols particularly proanthocyanidin (PAC)
(Heitmann, Nordeng, & Holst, 2013). There are two types of PACs, A-type and B-type,
based on the substitution pattern of their B-ring (Health et al., 2013). PACs in cranberry
are predominantly composed of A-type, whereas other berries mainly contain B-type
PACs (Health et al., 2013). The health benefits of cranberries to prevent or treat urinary
tract infection are documented. Recent observations from clinical trials also suggest
that increased consumption of cranberries attenuates inflammatory biomarkers,
hyperlipidemia, and hyperglycemia in obese individuals (Eftekhari, Allaei,
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Khosropanah, Rajaeifard, & Sohrabi, 2016; Health et al., 2013). Consistent with the
observations, several lines of in vivo evidence indicate that cranberry extract (CBE)
alleviates insulin resistance and inflammation in diet-induced obese mice (Anhê et al.,
2017, 2015). Moreover, in vitro studies support the anti-inflammatory potentials of
cranberries with the observations that CBEs inhibit the production of inflammatory
cytokines from several immune cell lines including RAW264.7, U937, and THP-1
(Bodet, Chandad, & Grenier, 2006; Hannon, Thompson, Khoo, Juturu, & Vanden
Heuvel, 2017; Huang, Yue, Dejan Nikolic, Susan Pendland, Brian J. Doyle, Tracie D.
Locklear, 2008; Moore et al., 2019). It was further revealed that CBE decreased NFκB-dependent transcriptional activity in human T lymphocytes using luciferase reporter
assay (Huang, Yue, Dejan Nikolic, Susan Pendland, Brian J. Doyle, Tracie D. Locklear,
2008). However, the underlying mechanisms by which CBE suppresses the
transcriptional activity of NF-κB for inducing pro-inflammatory genes in macrophages
have been still unclear.
Here we determined whether the anti-inflammatory effect of CBE is mediated
by

suppressing histone acetylation and NF-κB p65 phosphorylation, which are

required for transactivation of pro-inflammatory genes in macrophages and whether
such anti-inflammatory effects in macrophages are PAC-dependent using RAW 264.7
and primary mouse bone marrow-derived macrophages (BMDMs).

2.3.3. Materials & Methods
Materials
Cranberry extracts (CBEs) with two different PAC contents (5% and 15% PAC)
were generously provided from Artemis International (Fort Wayne, IN, USA). 2mercaptoethanol and lipopolysaccharide from E. Coli O111:B4 (LPS) were purchased
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from Sigma-Aldrich (St. Louis, MO, USA). Dulbecco’s modified Eagle’s medium
(high glucose, DMEM), Roswell Park Memorial Institute (RPMI) 1640 medium, fetal
bovine serum (FBS), penicillin/streptomycin, macrophage colony-stimulating factor
and Applied biosystem® SYBR® Green PCR Master Mix were purchased from
Thermo Fisher Scientific (Waltham, MA, USA).

Cell culture
RAW 264.7 cells (ATCC® TIB-71TM) were cultured in DMEM supplemented
with 10% FBS and 1% penicillin/streptomycin. The cells were seeded at the density of
1 x 105 cells/mL in 6-well plates and incubated overnight. Then, the cells were serumstarved for 1 hr and were subject to CBE-treatment. Bone marrow cells were kindly
provided by Dr. Jungwoo Lee (Dept. of Chemical Engineering, UMass Amherst). To
obtain bone marrow-derived macrophages (BMDMs), femurs and tibias were harvested
from FVB mice at 5 to 6 weeks old, and the bone marrow cells were flushed out and
cultured in RPMI 1640 supplemented with 10% FBS, 0.05 μM 2-mercaptoethanol and
1% penicillin/streptomycin overnight. Next day, the floating bone marrow cells were
collected, seeded in 6 well plates at the density of 0.2 x 106, and cultured in RPMI 1640
medium supplemented with 10% FBS and 1% penicillin/streptomycin in the presence
of M-CSF at 10 ng/mL for 5 days. For treatment, the both cell types were pretreated
with CBE for 1 hr, followed by 12-hr treatment with CBE in the presence of LPS (100
ng/mL). For western blot analysis, the cells were treated with CBE and LPS for 1 hr.

Nitric oxide (NO-) production from RAW 264.7 macrophages
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After 12-hr treatment with CBE in the presence of LPS, the cultured media were
collected, mixed with Griess reagent (Sigma-Aldrich) at the ratio of 1:1 and incubated
for 15 mins. The absorbance then was measured at 540 nm.

Quantitative real-time-PCR (qRT-PCR)
Total RNAs were isolated using TRIzolTM reagent (Thermo Fisher Scientific)
by following the manufacturer’s protocol, and cDNAs were synthesized using
RevertAid First Strand cDNA synthesis kit (Thermo Fisher Scientific). qRT-PCR was
performed using ViiATM 7 RT-PCR system (Life technologies, Grand Island, NY) to
analyze the mRNA expression levels of genes of interest. The target genes were
normalized by β-actin or 18S gene expression, and the relative expression was
calculated using the 2-(ΔΔnd). Primers used were mouse-specific and listed in Table 3.

Table 3. The list of primer sequences used

Western blotting
Cell lysates were prepared using RIPA buffer (Thermo Fisher Scientific)
supplemented with a protease and phosphatase inhibitor tablet and deacetylase inhibitor
cocktail (Thermo Fisher Scientific). For Western blot analysis, 20 g of lysates was
separated on 10% SDS polyacrylamide gel, transferred to PVDF membranes, and then
incubated with primary antibody overnight at 4°C, followed by secondary antibody
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incubation for 1 to 1.5 hr at room temperature. Primary antibodies including p65, p-p65
(Ser536), acyl-H3 and acyl-H4 were purchased from Cell Signaling Technology
(Beverly, MA, USA). Primary antibodies to HDAC3 and β-actin were purchased from
Santa Cruz Biotechnology Inc. (Santa Cruz, CA, USA). Then, the membrane was
incubated in ClarityTM Western ECL Blotting substrate (Bio-Rad, Hercules, CA) for 5
min and exposed to X-ray film. The band intensities were determined using ImageJ
software [National Institutes of Health (NIH), Bethesda, MD, US].

Statistics
The data were presented as the means ± S.D of three independent experiments
(n=3). To evaluate statistically significance, unpaired t-test was used, and the
differences were considered statistically significant at P < 0.05.

2.3.4. Results
CBE decreases NO production and Tnfα mRNA expression in LPS-stimulated
RAW 264.7 macrophages in a PAC concentration-dependent manner. First, we
investigated whether CBE suppresses macrophage inflammation and whether such antiinflammatory effects of CBE are PAC-dependent. We treated cells with 5% PAC- and
15% PAC-CBEs at 50 and 100 μg/mL concentrations 1-hr before and also during the
stimulation of RAW 264.7 macrophages with LPS for 12 hrs to measure NO production
and TNFα mRNA expression. Compared to unstimulated RAW 264.7 macrophages,
LPS significantly increased NO production (Fig. 9 A). In CBE-treated cells, both 5%
PAC- and 15% PAC-CBEs considerably decreased LPS-induced NO production at 100
μg/mL concentration. Similar to NO production, LPS greatly upregulated the
expression of Tnfα mRNA in RAW 264.7 macrophages when compared to
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unstimulated ones (Fig. 9 B). Treatment of 5% or 15% PAC-CBEs at concentrations of
50 and 100 μg/mL significantly decreased LPS-induced upregulation of Tnfα mRNA
level. 15% PAC-CBE treatment showed a stronger inhibitory effect on Tnfα mRNA
expression when compared to 5% PAC-CBE. The inhibitory effects of CBE on NO
production and Tnfα gene expression were PAC concentration-dependent and also in
agreement with previous studies (Bodet et al., 2006; Hannon et al., 2017; Huang, Yue,
Dejan Nikolic, Susan Pendland, Brian J. Doyle, Tracie D. Locklear, 2008; Moore et al.,
2019). We selected 50 μg/mL of both 5% PAC- and 15% PAC-CBEs for the further
experiments to address the anti-inflammatory effects on macrophages and potential
molecular mechanisms involved.
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Figure 9. The effects of CBE with either 5% or 15% PAC on NO production and Tnf expression in LPSstimulated RAW 264.7 macrophages. Cells were preincubated with CBE for 1 hour and co-treated with LPS
for 12 hours. The media were collected for NO production (A) and cells were harvested for RT-PCR (B). # P<0.05,
## P<0.01, ### P<0.001 as compared to control (unstimulated cells), * P<0.05, ** P<0.01, *** P<0.001 as compared
to only LPS-stimulated cell. Ψ P<0.05, ΨΨ P<0.01, ΨΨΨ P<0.001 as compared to 5% PAC-CBE-treated cells. n =
3, bars represent mean and S.D.
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CBE downregulates LPS-induced upregulation of pro-inflammatory mediators in
RAW 264.7 macrophages and BMDMs.
Next, we investigated the anti-inflammatory effects of CBE on macrophages in
RAW264.7 macrophage cell line as well as mouse BMDMs, which are the major source
of tissue macrophages and inflammation in obesity and metabolic disorders (Hill, Reid
Bolus, & Hasty, 2014; Zhao et al., 2018) (Fig. 10). LPS stimulation markedly
upregulated the mRNA levels of pro-inflammatory mediators such as iNos, Cox-2,
Tnfα, Mcp-1 and Il-6 in both RAW 264.7 macrophages and BMDMs compared to
unstimulated cells (Fig. 10 A-D). Treatment of cells with 5% and 15% PAC-CBEs at a
concentration of 50 μg/mL significantly inhibited LPS-induced upregulation of iNos,
Cox-2, Tnfα, Mcp-1 and Il-6 in both cell types. The inhibitory effects of CBE on LPSinduced expression of pro-inflammatory mediators in RAW264.7 macrophages were
statistically greater in the cells treated with 15% PAC-CBE than 5% PAC-CBE,
whereas no statistically significant difference between CBE-treated groups was
observed in BMDMs.
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Figure 10. CBE inhibited LPS-induced expression of proinflammatory genes in RAW264.7 macrophages and
mouse BMDMs. Cells were preincubated with CBEs for 1 hour and co-treated with LPS for 12 hours. The
data were analyzed as the fold change in gene expression normalized to a housekeeping gene (18S) and relative to
the LPS-stimulated cells. Gene expression from RAW 264.7 macrophages (A & B) and mouse BMDMs (C & D). #
P<0.05, ## P<0.01, ### P<0.001 as compared to control (unstimulated cells), * P<0.05, ** P<0.01, *** P<0.001 as
compared to only LPS-stimulated cell. Ψ P<0.05, ΨΨ P<0.01, ΨΨΨ P<0.001 as compared to 5% PAC-CBE-treated
cells. n = 3, bars represent mean and S.D.
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CBE suppresses phosphorylation of the NF-κB p65 and histone acetylation on
histone H4 in RAW 264.7 macrophages stimulated with LPS.
We next determined whether CBE suppresses the phosphorylation of NF-κB
p65 and/or histone acetylation to downregulate the expression of pro-inflammatory
mediators in LPS-stimulated macrophages (Fig. 11). LPS significantly increased the
phosphorylation of p65 without changing the protein expression of total p65 in
RAW264.7 macrophages. On the other hand, CBE with both 5% and 15% PAC
decreased the phosphorylation of p65 without affecting total p65 protein expression,
but statistically significant difference was observed from 15% PAC-CBE. Moreover,
while no differences in the levels of acyl-H3 and acyl-H4 as well as HDAC3 protein
expression were observed between LPS-stimulated and unstimulated cells, both 5% and
15% PAC-CBEs significantly increased the protein expression levels of HDAC3
compared to LPS-stimulated RAW 264.7 macrophages. Further, treatment of 15%
PAC-CBE showed a significant reduction in the acetylation levels of histone H4 protein,
but not H3 protein.
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Figure 11. CBE inhibits NF-κB p65 phosphorylation and histone H4 acetylation while increasing HDAC3
expression in LPS-stimulated RAW264.7 macrophages. After preincubation with CBE, cells were co-treated with
LPS for 1 hour, and proteins were obtained and analyzed with western blotting. Bands were quantified by
normalizing to β-actin. n = 3, bars represent mean and S.D. # P<0.05, ## P<0.01, ### P<0.001 as compared to control
(unstimulated cells), * P<0.05, ** P<0.01, *** P<0.001 as compared to only LPS-stimulated cell.
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CBE consistently targets p65 phosphorylation and histone H4 acetylation in
mouse BMDMs stimulated with LPS
To confirm that the anti-inflammatory effect of CBE was not limited to RAW
264.7 macrophage cell line, PAC-dependent effects on NF-κB p65, acyl-H3 and acylH4, and HDAC 3 protein abundance were carried out using mouse BMDMs. Similar to
the observations in RAW 264.7 macrophages, we found that treatment of CBE with
either 5% or 15% PAC greatly reduced the phosphorylation of p65 in LPS-stimulated
BMDMs without altering p65 protein expression levels (Fig. 12). The statistical
significance on the inhibition of p65 phosphorylation was observed in the cells treated
with 15% PAC-CBE. No differences in the acetylation levels of histone H3 and H4 and
HDAC3 protein abundance between LPS-treated and unstimulated cells were observed.
However, we found that CBE with either 5% or 15% PAC significantly decreased the
acetylation levels of histone H4, but not H3, when compared to LPS-treated BMDMs,
consistent with the observations made in RAW264.7 macrophages (Fig. 11). Moreover,
HDAC3 protein expression levels were significantly increased by 15% PAC-CBE
treatment, suggesting that CBE inhibits histone acetylation via HDAC3 expression.
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Figure 12 CBE suppresses p65 phosphorylation and histone H4 acetylation but increases HDAC3
expression in LPS-stimulated mouse BMDMs. After preincubation with CBEs, cells were co-treated with LPS
for 1 hour, and proteins were obtained and analyzed with western blotting. Bands were quantified by normalizing
to β-actin. n = 3, bars represent mean and S.D. # P<0.05, ## P<0.01, ### P<0.001 as compared to control
(unstimulated cells), * P<0.05, ** P<0.01, *** P<0.001 as compared to only LPS-stimulated cell.
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2.3.5. Discussion

Obesity-mediated chronic inflammation has been linked to increased incidence
of and deaths from metabolic diseases such as T2DM and CVD (Bonaccio et al., 2016).
The recruitment and the resultant activation of BMDMs in tissues are recognized as a
key cause of obesity-induced inflammation (Zhao, Zou, Du, & Zhao, 2018; Zheng et
al., 2016). Moreover, liposome-mediated deletion of visceral adipose macrophages
significantly suppressed the expression of genes for lipogenesis and pro-inflammatory
cytokines and concomitantly improved levels of serum lipids, glucose and insulin in
diet-induced obese mice (Bu et al., 2013). A body of evidence has also shown the antiinflammatory effects of cranberries in obese individuals and animals (Anhê et al., 2017;
Eftekhari et al., 2016; Health et al., 2013). Furthermore, in vitro studies using
RAW264.7, U937, and THP-1 suggest that extracts from cranberries inhibit the
production of pro-inflammatory cytokines by reducing the transcriptional activity of
NF-κB. However, little has been appreciated regarding the underlying mechanisms by
which cranberry extracts inhibits NF-κB transcriptional activity and the relevance of
potential mechanisms in BMDMs. Here we found the anti-inflammatory effects of CBE
on RAW 264.7 macrophages and primary mouse BMDMs, which are the major source
of tissue macrophages and inflammation in obesity (Hill et al., 2014; Zheng et al., 2016).
We also found that CBE significantly decreased LPS-induced upregulation of proinflammatory genes such as Tnfα, Mcp-1 and Il-6 by suppressing the NF-κB p65
phosphorylation in both RAW 264.7 macrophage cell line and mouse BMDMs.
Consistent with our data, Huang et. al. reported that cranberry extracts significantly
decreased the secretion of pro-inflammatory cytokines such as IL-6 and TNFα from
human peripheral mononuclear cells and inhibited NF-κB transactivation in human T
lymphocytes (Huang, Yue, Dejan Nikolic, Susan Pendland, Brian J. Doyle, Tracie D.

63

Locklear, 2008). Furthermore, La et. al. demonstrated that PACs isolated from
cranberries dose-dependently suppressed the release of pro-inflammatory cytokines
and inhibited NF-κB p65 transactivation in oral epithelial cells (La, Howell, & Grenier,
2010). Therefore, these comparable and consistent observations support the antiinflammatory properties of cranberries, indicating that cranberry-originated PAC
targets NF-κB p65-mediated inflammatory responses in immune cells, including
macrophages as supported by the current findings.
To the best of our knowledge, this is the first study that CBE increased the
protein expression level of HDAC3 with a concomitant decrease in the acetylation level
of histone H4, but not H3, in both RAW 264.7 macrophage cell line and mouse
BMDMs. In quiescent state, it is reported that the promoter regions of inflammatory
genes are restrained by histone deacetylation, and HDAC3 is identified as a key
regulator of the histone deacetylation in mouse BMDMs (Barish et al., 2010). Upon
activation, phosphorylated p65 subunit, which forms a heterodimer with p50
accompanies histone acetylation and binds to its element to induce the expression of
pro-inflammatory genes (Barish et al., 2010; Viatour et al., 2005). In line with this, it
was reported that trichostatin A (TSA), an inhibitor of HDAC, significantly promoted
LPS-induced inflammatory responses in mouse BMDMs (Aung et al., 2006). Given the
epigenetic regulation of NF-κB p65 signaling, our findings may indicate that PAC-rich
CBE increases the expression levels of HDAC3, resulting in reduced the acetylation of
histone H4, which in turn prevent NF-κB p65-mediated inflammatory responses in
tissue macrophages. The differential regulation of CBE-mediated histone acetylation
on histone H3 and H4 may indicate that, as reported by Ito et. Al. (Ito, Barnes, &
Adcock, 2000), the level of acetylation of histone H3 may not be as rapid as that of
histone H4 in response to inflammatory stimuli. This is also consistent with the
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observation made by Choi et al (Choi et al., 2015), where LPS-induced inflammatory
response in RAW264.7 macrophages was inhibited by veratric acid with concomitantly
increased deacetylation of histone H4, but not H3. Therefore, the epigenetic regulation
of HDAC3 by PAC-rich CBE promotes HDAC3 expression that may serve as an
additional potential molecular mechanism for suppressing the NF-κB p65-dependent
inflammatory responses in macrophages.
In conclusion, our current study demonstrated that PAC-rich CBE inhibits LPSinduced inflammatory responses in RAW264.7 macrophages and mouse BMDMs.
Potential mechanisms are suggested to be through the suppression of the NF-κB p65
phosphorylation and acetylation levels of histone H4 with a concomitant increase in
HDAC3 protein expression in both cell types. Therefore, these findings warrant further
investigations in preclinical and/or clinical in vivo models.
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2.4. Sulforaphane (SFN) attenuates LPS-induced inflammation activation of
RAW 264.7 macrophage and bone marrow-derived macrophage (BMDMs) via
the inhibition of NF-κB activation
2.4.1. Abstract
Substantial evidence indicates that obesity-related chronic inflammation
promotes morbidity and mortality of metabolic disorders in humans. Accumulated
evidence suggests sulforaphane (SFN), which is a major bioactive of brussels sprout
and broccoli, as an anti-inflammatory agent. However, a potential molecular
mechanism has been unclear. The nuclear factor-kappa B (NF-κB) activation in
macrophage is recognized as a key signaling pathway for obesity-related chronic
inflammation in tissues. Moreover, histone acetylation facilitates the NF-κB p65mediated transactivation of inflammatory genes. Therefore, we investigated whether
SFN suppresses p65 phosphorylation and histone acetylation in macrophages using
RAW 264.7 and mouse bone marrow-derived macrophages (BMDMs). In LPSstimulated RAW 264.7 macrophages, SFN greatly upregulated the expression of its
known target genes (Nrf2 and Ho-1) with a concomitant reduction in the production of
O2- and NO- and significantly suppressed CD11c fluorescence intensity and
inflammatory genes (iNos, Cox-2, Tnfα, Mcp-1 and Il-6). Moreover, SFN remarkedly
inhibited p65 phosphorylation and acetylation levels of histone H4 while increasing
HDAC3 expression in the cells. Consistently, SFN significantly increased the
expression levels of Nrf2 and Ho-1 but considerably downregulated the expression of
inflammatory genes in mouse BMDMs. Moreover, SFN inhibited p65 phosphorylation
as well as histone H4 acetylation with a concomitant increase in HDAC3 expression in
the cells. Collectively, these observations provide potential mechanisms by which SFN
suppresses macrophage inflammation. SFN-rich diets or supplement may serve as a
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dietary anti-inflammatory agent that will help lower chronic inflammation in obesity
and its related metabolic disorders.

2.4.2. Introduction

Obesity-related sustained inflammation is closely linked to increased morbidity
and mortality of metabolic disorders such as type 2 diabetes mellitus (T2DM) and
cardiovascular disease (CVD) (Bonaccio et al., 2016). Substantial evidence indicates
that obesity-related monocyte/macrophage accumulation and subsequent inflammatory
activation serve as important mechanisms for sustained local and systemic
inflammation (C. Zheng et al., 2016). There are multiple anti-inflammatory drugs
commercially available such as nonsteroidal anti-inflammatory drugs (NSAIDs)
(Gislason et al., 2009). However, safety concerns have been raised due to side effectsrelated increased mortality in patients with metabolic disorders in clinical trials (T. A.
Lee, Bartle, & Weiss, 2007; Pollack, Donath, LeRoith, & Leibowitz, 2016). It has been
shown that increased consumption of certain fruits and vegetables is shown to attenuate
obesity-related inflammation in humans and animals (Gislason et al., 2009). Therefore,
dietary approaches would be an alternative way to attenuate chronic inflammation in
metabolic diseases.
Nuclear factor-kappa B (NF-κB) is a key transcription factor for macrophage
inflammation and accumulation, inducing distinct surface markers including CD11c+
and expression of pro-inflammatory genes such as inducible nitric oxidase (iNOS),
tumor necrosis factor alpha (TNFα), interleukin-6 (IL-6) and monocyte chemoattractant
protein-1 (MCP-1) (Boutens & Stienstra, 2016; A. A. Hill et al., 2015). NF-κB family
is composed of five proteins such as p65 (Rel-A), Rel-B, c-Rel, p52, and p50. Among
them, the NF-κB p65 subunit which forms a heterodimer with p50 has gained attention
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as a major target against obesity-related chronic inflammation due to the significant
increase of p65-dependnet macrophage accumulation and inflammatory response in
metabolic diseases (Giridharan & Srinivasan, 2018; A. A. Hill et al., 2015). The
transactivation of pro-inflammatory genes by p65 requires the phosphorylation of p65
and histone acetylation on the promoter regions of pro-inflammatory genes, which are
constrained via histone deacetylation, so that p-p65 binds to its responsive element
(Barish et al., 2010; Viatour et al., 2005). It has been further revealed that among
histone deacetylases (HDACs), HDAC 3 plays a pivotal role in the regulation of histone
deacetylation of pro-inflammatory genes in macrophages (Barish et al., 2010).
Therefore, targeting p65 phosphorylation or/and HDAC3 expression would serve as
molecular strategies for obesity-related chronic inflammation.
Sulforaphane (SFN) is a metabolite of glucoraphanin which is abundantly found
in cruciferous vegetables such as broccoli and brussels sprouts. SFN is well-known as
an inducer of NF-E2-related factor (NRF2) activation, which induces the expression of
antioxidant enzymes such as glutathione reductase (GR) and heme oxygenase-1 (HO1), and is also shown to act as an inhibitor of histone deacetylases which leads to cell
cycle arrest and apoptosis of cancer cells (Myzak, Dashwood, Orner, Ho, & Dashwood,
2006b; Ruhee, Ma, & Suzuki, 2019). Moreover, accumulated in vivo and in vitro
evidence indicates that SFN may attenuate obesity-related inflammation and metabolic
dysregulations (Lin et al., 2008; Nagata et al., 2017; Ruhee et al., 2019). In diet-induced
obese mice, glucoraphanin supplementation significantly reduced hepatic inflammation
and CD11c+ macrophage accumulation, suggesting NRF2 activation as a potential
mechanism (Nagata et al., 2017). In line with the suggestion, it was reported that the
anti-inflammatory effects of SFN on lipopolysaccharide (LPS)-induced inflammation
in peritoneal macrophages were attenuated by Nrf2 knockout (KO) (Lin et al., 2008).
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However, a potent inhibitory effects of SFN on the secretion of pro-inflammatory
cytokines including IL-1β, TNFα and PGE2 in LPS-stimulated Nrf2 KO peritoneal
macrophages still existed and statistically significant, when compared to LPSstimulated control cells (Lin et al., 2008). This would suggest that there would be a
potential mechanism for the anti-inflammatory effects of SFN on macrophages which
would be independent of Nrf2 activation. Indeed, it was shown that glucoraphanin
supplementation attenuates p65 phosphorylation in the liver from diet-induced obese
mice (Nagata et al., 2017), questioning whether SFN targets p65 activation to exert
anti-inflammatory potentials. Here we investigated whether SFN inhibits p65
phosphorylation and histone acetylation in macrophages using RAW 264.7 and mouse
bone marrow-derived macrophages (BMDMs) in an attempt to understand a potential
molecular mechanism for the anti-inflammatory effects of SFN in obesity. We chose
the concentration range ≤ 20 μM which is physiologically achievable in mice and is
consistent with previous studies (Li, Zhang, Zou, Schwartz, & Sun, 2013; Lin et al.,
2008; Ruhee et al., 2019)

2.3.3. Materials & Methods
Materials
L-Sulforaphane (SFN) was obtained from Santa Cruz Biotechnology (Santa
Cruz, CA, USA). Lipopolysaccharide from E. Coli O111:B4 (LPS) and 2mercaptoethanol were purchased from Sigma-Aldrich (St. Louis, MO, USA).
Dulbecco’s modified Eagle’s medium (high glucose, DMEM), Roswell Park Memorial
Institute (RPMI) 1640 medium, penicillin/streptomycin (P/S), fetal bovine serum (FBS),
macrophage colony-stimulating factor were purchased from Thermo Fisher Scientific
(Waltham, MA, USA).
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Cell culture
RAW 264.7 macrophages (ATCC® TIB-71TM) were propagated in DMEM
containing 10% FBS and 1% P/S. 1 x 105 cells/mL was seeded in 6-well plates and
incubated overnight. Next day, the cells were subject to SFN-pretreatment for 1 hour
followed by 12-hour treatment of SFN in the presence of LPS (100 ng/mL). For the
experiments with bone marrow-derived macrophages (BMDMs), femurs and tibias
were harvested from FVB mice at 4-5 weeks old, and the bone marrow cells were
collected and cultured in RPMI 1640 medium containing 10% FBS, 0.05 μM 2mercaptoethanol and 1% P/S overnight. Next day, the floating bone marrow cells were
collected, seeded in 6-well plates at the density of 0.2 x 106 cells/mL, and differentiated
into BMDM in RPMI 1640 medium containing 10% FBS, 1% P/S, 0.05 μM 2mercaptoethanol and M-CSF at 10 ng/mL for 5 days. Then, the cells were pre-treated
with SFN for 1-hour and co-treated with LPS for 12 hours. For western blot analysis,
the cells were co-treated with SFN and LPS for 1 hour.

Nitric oxide (NO-) production
After 12-hr treatment with SFN in the presence or absence of LPS, the cultured
media from RAW 264.7 macrophages were collected, mixed with Griess reagent
(Sigma-Aldrich) at the ratio of 1 to 1 and incubated for 15 mins. The absorbance was
measured at 540 nm.

Nitroblue tetrazolium (NBT) assay
O2- production was measured as previously described (O. H. Lee, Kwon,
Apostolidis, Shetty, & Kim, 2011). After SFN treatment for 12 hours in the presence
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or absence of LPS, RAW 264.7 macrophages were exposed to 0.2% NBT in PBS for
60 min. Formazan was dissolved with dimethyl sulfoxide (DMSO), and the absorbance
was measured at 570 nm.

Quantitative real-time-PCR (qRT-PCR)
Total RNAs were isolated using TRIzolTM reagent (Thermo Fisher Scientific)
and cDNAs were obtained using RevertAid First Strand cDNA synthesis kit (Thermo
Fisher Scientific) by following the manufacturer’s protocol. qRT-PCR was performed
using ViiATM 7 RT-PCR system (Life technologies, Grand Island, NY). The target
genes were normalized by 18S gene expression, and the relative expression was
calculated using the 2-(ΔΔnd). Primers used were mouse-specific and listed in Table 1.

Table 4. The list of primer sequences used

Immunofluorescence (IF) analysis
Briefly, cells were grown in 4-well chamber slides and received a designated
treatment. Then, the cells were fixed with 4.5% paraformaldehyde for 20 min and
permeabilized with 0.5% Triton X-100 for 10 min at RT. For IF staining, the cells were
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blocked in 2% BSA-containing PBS supplemented with 0.1% tween 20 (PBST) for 1
hour at RT, incubated with primary antibody (1:200) in PBST overnight at 4°C,
followed by the incubation with secondary antibody (1:500) overnight at 4°C. Imaging
for the immune-labeled cells was performed using EVOSTM M5000 (Thermo Fisher
Scientific), and the images were processed using the Adobe Photoshop (Adobe System,
San Jose, CA).

Western blotting
Cell lysates were prepared using RIPA buffer (Thermo Fisher Scientific)
supplemented with a protease and phosphatase inhibitors and deacetylase inhibitor
cocktail (Thermo Fisher Scientific). 20 μg of lysates was separated on 10% SDS
polyacrylamide gel, transferred to PVDF membranes, and then incubated with primary
antibody overnight at 4°C, followed by secondary antibody incubation for 1 to 1.5 hr
at room temperature. Primary antibodies including p65, p-p65 Ser536, acyl-H3 and
acyl-H4 were purchased from Cell Signaling Technology (Beverly, MA, USA).
Primary antibodies to HDAC3 and β-actin were purchased from Santa Cruz
Biotechnology Inc. (Santa Cruz, CA, USA). Then, the membrane was incubated in
ClairtyTM Western ECL Blotting substrate (Bio-Rad, Hercules, CA) for 5 min and
exposed to X-ray film. The band intensities were determined using ImageJ software
[National Institutes of Health (NIH), Bethesda, MD, US].

Statistics
The data were presented as the means ± S.D of three independent experiments
(n=3). To evaluate statistically significance, unpaired t-test was used, and the
differences were considered statistically significant at P < 0.05.
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2.3.4. Results
SFN treatment exerts anti-oxidant effects on RAW 264.7 macrophages.
SFN exerts antioxidant effects Nrf2-dependently by inducing its related downstream target genes such as heme oxygenase-1 (HO-1) (Lin et al., 2008). Therefore, we
first investigated the antioxidant effects of SFN on RAW264.7 macrophages to ensure
that SFN works at the molecular level as previously known in our cell culture model
(Fig. 13). While LPS did not affect, SFN significantly increased the expression levels
of Nrf2 and Ho-1 genes in RAW264.7 macrophages when compared to LPS-stimulated
cells. The mRNA expression levels of Ho-1 were statistically greater in the cells treated
with 20 μM than with 10 μM. Next, we measured the production of ROS (O2-) and RNS
(NO-) in RAW 264.7 macrophages. LPS significantly increased the production of O2and NO- in RAW 264.7 macrophages compared to unstimulated cells, whereas SFN
significantly inhibited LPS-induced O2- and NO- levels in a dose-dependent manner.
Therefore, we found that SFN exerts antioxidant effects on RAW264.7 macrophages
perhaps via Nrf2-dependent mechanisms, as previously known (Lin et al., 2008).
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Figure 13. The effects of SFN on the expression of Nrf2 and Ho-1 genes and production of superoxide anion
(O2-) and nitric oxide (NO-) in LPS-stimulated RAW 264.7 macrophages. Cells were preincubated with SFN
for 1 hour and co-treated with LPS for 12 hours. (A) Gene expression by RT-PCR and (B) O2- and NO- production.
# P<0.05, ## P<0.01, ### P<0.001 as compared to control (unstimulated cells), * P<0.05, ** P<0.01, *** P<0.001
as compared to only LPS-stimulated cell. Ψ P<0.05, ΨΨ P<0.01, ΨΨΨ P<0.001 as compared to SFN at 10 μM. n =
3, bars represent mean and S.D.
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SFN suppresses LPS-induced expression of CD11c and inflammatory genes in RAW
264.7 macrophages.
It was reported that SFN suppresses the accumulation of CD11c+ macrophages
and inflammation in the liver in diet-induced obese mice (Nagata et al., 2017). We next
evaluated the effects of SFN on LPS-induced pro-inflammatory activation in
RAW264.7 macrophages through the analyses of CD11c immunofluorescence staining
and expression of pro-inflammatory genes (Fig. 14). LPS-stimulated cells exhibited
greater CD11c fluorescent intensity than unstimulated ones. SFN treatment, however,
reduced CD11c fluorescent intensity in RAW 264.7 macrophages at 10 and 20 μM.
Moreover, SFN significantly decreased LPS-induced upregulation of expression of
inflammatory genes such as iNos, Cox-2, Tnfα, Mcp-1 and Il-6 in RAW 264.7
macrophages when compared to LPS-stimulated ones. The inhibitory effects of SFN
on LPS-induced inflammation in RAW264.7 macrophages were dose-dependent when
SFN-treated groups were compared. Therefore, these data may suggest that SFN
suppresses inflammation activation in RAW264.7 macrophages stimulated with LPS.
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Figure 14. The effects of SFN on CD11c fluorescence intensit and expression of pro-inflammatory genes in
LPS-stimulated RAW 264.7 macrophages. Cells were preincubated with SFN for 1 hour and co-treated with LPS
for 12 hours. (A) Representative picture of CD11c immunofluorescence staining. (B) Gene expression by RT-PCR.
# P<0.05, ## P<0.01, ### P<0.001 as compared to control (unstimulated cells), * P<0.05, ** P<0.01, *** P<0.001
as compared to only LPS-stimulated cell. Ψ P<0.05, ΨΨ P<0.01, ΨΨΨ P<0.001 as compared to SFN at 10 μM. n =
3, bars represent mean and S.D.
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SFN suppresses the phosphorylation of p65 and acetylation levels of histone H4 and
increases HDAC3 expression in RAW 264.7 macrophages.
It was shown that the anti-inflammatory effects of SFN on macrophages would
be independent of Nrf2-mediated antioxidant effects (Lin et al., 2008). To gain insight
into potential mechanisms by which SFN inhibits LPS-induced inflammation in
RAW264.7 macrophages, we investigated the effects of SFN on p65 phosphorylation
and histone deacetylation (Fig. 15). Consistent with mRNA expression data, we found
that, while LPS increased, SFN significantly decreased p65 phosphorylation. However,
neither LPS nor SFN changed p65 protein expression levels in the cells. In addition, we
found that SFN significantly increased the expression levels of HDAC3 at 20 μM.
Consistently, we also found that SFN greatly suppressed the acetylation levels of
histone H4, but not H3, in RAW 264.7 macrophages, showing the inverse correlation
between HDAC3 expression and histone H4 acetylation levels. It was also observed
that LPS stimulation increased HDAC3 expression in RAW 264.7 macrophages.
However, no changes on the acetylation levels of histone H3 and H4 indicate that LPSinduced HDAC3 expression is negligible. Therefore, these findings indicate that SFN
may exert anti-inflammatory effects on macrophages by targeting p65 phosphorylation
or/and HDAC3 expression.
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Figure 15. The effects of SFN on p65 phosphorylation, histone acetylation and HDAC3 expression in LPSstimulated RAW 264.7 macrophages. (A) p65 and p-p65 protein expression. (B) Representative picture of HDAC3,
acyl-H4 and acyl-H3. # P<0.05, ## P<0.01, ### P<0.001 as compared to control (unstimulated cells), * P<0.05, **
P<0.01, *** P<0.001 as compared to only LPS-stimulated cell. Ψ P<0.05, ΨΨ P<0.01, ΨΨΨ P<0.001 as compared
to SFN at 10 μM. n = 3, bars represent mean and S.D.
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SFN upregulates the expression antioxidant genes and suppresses anti-inflammatory
genes in mouse BMDMs stimulated LPS.
The recruitment of bone marrow-derived monocytes and following
differentiation into macrophages are identified as key mechanisms for obesity-related
chronic inflammation in tissues (C. Zheng et al., 2016). To test the in vivo relevance of
anti-inflammatory effects of SFN on macrophages in obesity, we cultured bone marrow
monocytes, differentiated into macrophages, and stimulated with LPS in the presence
of SFN at the same concentrations for RAW 264.7 macrophages (Fig. 16). Unlike the
findings from RAW 264.7 macrophages, LPS significantly reduced Nrt2 gene
expression when compared to unstimulated cells. However, consistent with RAW 264.7
cell data, SFN significantly increased the expression of Nrf2 and Ho-1 genes at 20 M
when compared to BMDMs treated with only LPS. Moreover, we found that SFN at 20
M significantly decreased LPS-induced expression of inflammatory genes such as
iNos, Cox-2, Tnf, Mcp-1 and Il-6 in BMDMs. At 10 M, SFN inhibited iNos, Mcp-1
and Il-6 only in the cells. Therefore, we consistently found the inhibitory effects of SFN
on macrophage inflammation in mouse BMDMs.
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Figure 16. The effects of SFN on the expression of anti-oxidant or pro-inflammatory genes in LPS-stimulated
mouse BMDMs. Cells were preincubated with SFN for 1 hour and co-treated with LPS for 12 hours. (A & B)
Gene expression by RT-PCR. # P<0.05, ## P<0.01, ### P<0.001 as compared to control (unstimulated cells), *
P<0.05, ** P<0.01, *** P<0.001 as compared to only LPS-stimulated cell. Ψ P<0.05, ΨΨ P<0.01, ΨΨΨ P<0.001 as
compared to SFN at 10 μM. n = 3, bars represent mean and S.D.
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SFN suppresses p65 phosphorylation and increases HDAC3 expression in BMDMs.
Potential mechanisms by which SFN suppresses LPS-induced upregulation of
proinflammatory genes were investigated in mouse BMDMs (Fig. 17). As consistent
with findings in RAW264.7 macrophages, we found that SFN at 20 M remarkably
reduced the phosphorylation of p65 subunit in BMDMs. Moreover, neither LPS nor
SFN alters the expression levels of p65 in the cells. In addition, we observed that SFN
at 20 M significantly increased the expression levels of HDAC3 with a concomitant
decrease in the acetylation levels of histone H4, not H3, in BMDMs stimulated with
LPS. As consistent with the findings in RAW 264.7 macrophages, these observations
indicate the potential inhibitory roles of SFN in p65 phosphorylation or/and histone H4
acetylation in macrophages, both of which will downregulate the transactivation of
proinflammatory genes.
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Figure 17. The effects of SFN on p65 phosphorylation, histone acetylation and HDAC3 expression in LPSstimulated BMDMs. (A) p65 and p-p65 protein expression. (B) Representative picture of HDAC3, acyl-H4 and
acyl-H3. # P<0.05, ## P<0.01, ### P<0.001 as compared to control (unstimulated cells), * P<0.05, ** P<0.01, ***
P<0.001 as compared to only LPS-stimulated cell. Ψ P<0.05, ΨΨ P<0.01, ΨΨΨ P<0.001 as compared to SFN at 10
μM. n = 3, bars represent mean and S.D.
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2.3.5. Discussion
It is well established that obesity-related chronic inflammation is related to
increased morbidity and mortality of metabolic disorders such as T2DM and CVD.
Recent in vivo and in vitro evidence indicates that SFN which is a major bioactive
compound of cruciferous vegetables may attenuate macrophage accumulation and
inflammation in obesity (Lin et al., 2008; Nagata et al., 2017; Ruhee et al., 2019).
However, potential mechanisms for the anti-inflammatory effects of SFN on
macrophages have been unclear. In this study, we found that SFN suppressed LPSinduced inflammation activation in RAW264.7 macrophages as evidenced by reduced
the fluorescence intensity of CD11c surface marker and expression of proinflammatory mediators. The inhibitory effects of SFN on LPS-induced upregulation
of pro-inflammatory genes were consistently observed in mouse BMDMs which are
the major source of obesity-related tissue inflammation (C. Zheng et al., 2016). These
observations are consistent with the previous observations in RAW264.7 and peritoneal
macrophages published by other groups (Lin et al., 2008; Ruhee et al., 2019). Moreover,
we found that SFN inhibits p65 phosphorylation in both RAW 264.7 and mouse
BMDMs. The disproportionate increase in p65-mediated inflammatory response has
been suggested as a key mechanism for obesity-related chronic inflammation and
macrophage accumulation (Giridharan & Srinivasan, 2018). Nagata et al reported that
the SFN precursor molecule, glucoraphanin, significantly reduced diet-induced hepatic
macrophage inflammation and CD11c-expressing macrophages with a concomitant
decrease in p65 phosphorylation in vivo (Nagata et al., 2017). Therefore, our findings
may suggest the suppression of p65 phosphorylation by SFN as a potential mechanism
for the anti-inflammatory effects of SFN on macrophages.
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Histone acetylation on the promoter regions of pro-inflammatory genes is
required for p65-mediated inflammatory response in macrophages (Barish et al., 2010).
It has been reported that the treatment of trichostatin A (TSA), an inhibitor of HDAC,
enhanced LPS-induced inflammation in mouse BMDMs (Aung et al., 2006). HDAC3
is a key mediator of restraining the expression of pro-inflammatory genes during
quiescent state in human and mouse macrophages (Barish et al., 2010; Winkler, Nocka,
& Williams, 2012). To the best of our knowledge, we found that SFN increases the
expression levels of HDAC3 and concomitantly reduced the acetylation levels of
histone H4 in both RAW 264.7 macrophages and BMDMs. In contrast to our findings,
it has been shown that SFN suppresses HDAC activity and expression in cancer cells,
serving as a key molecular mechanism for inducing cancer cell apoptosis (Myzak,
Dashwood, Orner, Ho, & Dashwood, 2006a). However, Chen et al recently reported
that SFN reduced the acetylation levels of histone H3 and H4 in HaCaT keratocytes
and HCT116 colon cancer cells while TSA enhances histone H3 and H4 acetylation
levels, raising a question whether SFN acts as an inhibitor of HDACs (Douglas Fields,
2015). Consistently, our findings indicate that SFN increases HDAC3 expression with
a concomitant decrease in histone H4 acetylation, suggesting that the epigenetic role of
SFN in the regulation of histone deacetylation would suppress the transactivation of
pro-inflammatory genes by p-p65 in addition to inhibiting p65 phosphorylation in
macrophages. We observed the different regulation of histone acetylation on histone
H3 and H4, showing only a significant reduction in histone H4 acetylation by SFN in
RAW 264.7 macrophages and mouse BMDMs. This could be explained by the
observation that the acetylation levels of histone H4 is rapidly changed in response to
inflammatory stimuli, whereas does not histone H3 (Ito, Barnes, & Adcock, 2000).

84

In conclusion, we have demonstrated that SFN, which is a major bioactive
compound of cruciferous vegetables such as brussels sprout and broccoli, exerts antiinflammatory effects on RAW264.7 and mouse BMDMs stimulated with LPS.
Potential mechanisms would be mediated by the inhibition of p65 phosphorylation
or/and HDAC3 protein expression, which suppresses the transactivation of
inflammatory genes. Collectively, these observations indicate that SFN-rich vegetables
or supplement may serve as a dietary anti-inflammatory agent that will help lower
chronic inflammation and its related health outcomes such as increased morbidity and
mortality of metabolic disorders.
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3. The Role of Obesity-Elevated Tumor Necrosis Factor Alpha (TNFα) in AT
Metabolism and Inflammation
3.1. The genetic ablation of TNFα attenuates hepatic steatosis and insulin
resistance by promoting fatty acid metabolism in adipose tissue
3.1.1. Abstract
In obesity, adipose tissue (AT) exhibits sustained inflammation and disrupted
lipid metabolism, promoting the development of hepatic steatosis and insulin resistance.
Accumulated evidence suggests that tumor necrosis factor alpha (TNFα), a key
mediator of tissue inflammation, promotes fat depositions in tissues in response to a
high-fat diet (HFD) in mice. However, the potential roles played by TNFα in fatty acid
metabolism in AT and the liver in vivo have been incompletely understood. Wild-type
male mice were fed either a low-fat diet (LFD-WT) or a HFD (HFD-WT) and TNFα
knockout male mice were fed an HFD (HFD-TNFα KO) for 16 weeks. Blood
concentrations of glucose and insulin and hepatic triacylglycerol (TG) levels were
measured. The expression of genes involved in fatty acid metabolism was measured in
epididymal white AT (eWAT) and the liver. Compared to the LFD-WT group, HFDWT group had significantly higher levels of blood glucose and insulin and hepatic TG,
whereas TNFα KO significantly attenuated such diet-induced metabolic alterations,
hyperglycemia, hyperinsulinemia and hepatic TG accumulation. In eWAT, TNFα KO
mitigated HFD-suppressed expression of proteins related to TG hydrolysis and FAO.
In the liver, TNFα KO reduced HFD-induced upregulation of expression of genes
related to FA uptake and TG synthesis. In addition, TNFα KO significantly reduced the
expression of pro-inflammatory genes and macrophage markers in eWAT otherwise
considerably increased as observed in the HFD-WT group. These data indicate that
antagonizing TNFα or its expression in AT may mitigate diet-induced hepatic steatosis
and insulin resistance by promoting FA metabolism in AT.
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3.1.2. Introduction
Obesity is characterized by sustained low-grade inflammation and disturbed
lipid metabolism in tissues, contributing to the development of chronic disorders such
as non-alcoholic fatty liver disease (NAFLD), insulin resistance, type 2 diabetes
mellitus (T2DM) (De Luca & Olefsky, 2006). Obesity has been tripled in the U.S. since
1975, affecting 42.4% of adults in 2017-2018 (Craig M. Hales, Margaret D. Carroll,
Cheryl D. Fryar, 2020). Moreover, recent predictive model based on the prevalence of
obesity in children and adolescents estimates that half of the U.S. adults will be obese
by 2030 (Finkelstein et al., 2012). In parallel, the prevalence of NAFLD and T2DM in
the U.S. is also expected to increase about 36% and 54% respectively from 2015 to
2030 (Estes, Razavi, Loomba, Younossi, & Sanyal, 2018; Rowley, Bezold, Arikan,
Byrne, & Krohe, 2017). However, there is no pharmaceutics proved to treat NAFLD.
The remission rates of T2DM with current anti-diabetic drugs are as low as 3% in the
U.S adults and 2% in those aged over 65 which drop down in following years (Gregg
et al., 2012; Tangelloju, Little, Esterhay, Brock, & LaJoie, 2019). This would ascribe
to a limited understanding of physio-pathogenesis for obesity-related metabolic
disorders.
Adipose tissue (AT) serves as the primary energy reservoir of the body and
maintains its metabolic flexibility through the balance between triglyceride (TG)
storage and fatty acid oxidation (FAO), which is termed lipid turnover, as it has limits
with regard to expandability and capacity to store lipids in humans (P. Arner et al., 2011;
Duwaerts & Maher, 2019; Rydén et al., 2013; Spalding et al., 2008). The liver appears
to be secondary, taking up about 33% to 36% of dietary fats (Duwaerts & Maher, 2019).
In obese individuals, AT is composed of fully enlarged adipocytes and exhibits
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decreased lipid turnover due largely to disrupted hormone-mediated lipolysis and FAO
(P. Arner et al., 2011; Frayn et al., 2012; Langin et al., 2005; Rydén et al., 2013). Also,
monocytes/macrophages are increasingly infiltrated and over-polarized into
inflammatory

macrophages

in

AT,

constituting

sustained

proinflammatory

microenvironment (E. Arner et al., 2010). As AT loses its flexibility, metabolic burden
to the liver increases by accommodating more FAs and upregulating the expression of
lipogenesis-related genes (Utzschneider & Kahn, 2006). If left untreated, it has been
shown that the liver develops hepatic steatosis and subsequently inflammation and
fibrosis, leading to systemic insulin resistance (Reid et al., 2008). However, a potential
mechanism for decreased AT lipid turnover during the development of obesity has been
unclear. Therefore, understanding such potential mechanism(s) would lay foundation
for the development of potential pharmaceutics or/and dietary approaches against
obesity-related metabolic complications.
Proinflammatory tumor necrosis factor alpha (TNFα) is a key mediator of tissue
inflammation and is overexpressed in AT in obese humans and animals (Hotamisligil
GS et al., 1993; Isakson et al., 2009b; Parameswaran & Patial, 2010). Several lines of
in vivo evidence indicate the involvement of TNFα in disturbed lipid metabolism in
tissues in diet-induced obesity (Bouter et al., 2010; De Taeye et al., 2007; Salles et al.,
2012; Uysal, Wiesbrock, Marino, & Hotamisligil, 1997). Upon chow diet, TNFα
knockout (KO) mice showed no effects on AT mass and hepatic TG accumulation when
compared to wild-type (WT) mice (Bouter et al., 2010). However, while the exposure
to a high-fat diet (HFD) for as short as 4 and as long as 26 weeks increases body weight,
adipocyte size, and hepatic TG contents with a concomitant development of glucose
intolerance in WT mice, the development of such diet-induced metabolic outcomes by
HFD were resistant in TNFα KO mice (Bouter et al., 2010; De Taeye et al., 2007; Salles
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et al., 2012). The resistance of HFD-induced adiposity and weight gain by TNFα KO
is consistently observed in our recently study (Under review by co-author). These
observations indicate the role that TNFα plays in promoting fat accumulation in tissues
in response to an HFD, contributing to the development of insulin resistance. However,
the potential roles played by TNFα in FA metabolism in AT and the liver in vivo have
been incompletely understood.
Here we investigated the role of TNFα in TG synthesis and hydrolysis and FA
synthesis and oxidation in adipose and liver tissues in response to a 16-week HFD
feeding using WT and TNFα KO mice, which was the average feeding period given the
weeks followed by previous studies (Bouter et al., 2010; De Taeye et al., 2007; Salles
et al., 2012). We hypothesized that TNFα decreases lipid turnover in AT by inducing
metabolic defects in TG hydrolysis and FAO and thereby promotes the development of
hepatic steatosis and insulin resistance in mice.

3.1.3. Materials & Methods
Animal experiments.
All experiments were approved by the Institutional Animal Care and Use
Committee of the Jean Mayer USDA Human Nutrition Research Center on Aging at
Tufts University and the Institutional Animal Care and Use Committee of the
University of Massachusetts, Amherst. As reported previously, 8-week-old C57BL/6
wildtype (WT) male mice were divided into two groups which fed either a low-fat diet
(LFD-WT, 10 kcal% fat) or a high-fat diet (HFD-WT, 60% kcal% fat). The TNFα KO
mouse model, purchased from Jackson Laboratory (Bar Harbor, ME), which was
created on a 129S/6 background, has been backcrossed to C57BL/6 for >5 generations.
The TNFα KO were fed the same HFD (HFD-TNFα KO). The diet composition and
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procedures for sacrificing mice, collecting blood and tissues are available in the
previous study (under review by co-authors).

Analytical methods for blood biomarkers and hepatic triglyceride (TG)
Plasma glucose levels were measured using glucose oxidase assay kit (Sigma,
St. Louis, MO). Plasma insulin levels were measured using mouse insulin ELISA kit
(Linco Research, St Charles, MO). For the determination of hepatic TG, triglyceride
assay kit (Cayman Chemical, Ann Arbor, MI) was used.

Quantitative real-time polymerase chain reaction (RT-PCR)
Total RNAs were obtained using TRIzolTM reagent (Thermo Fisher Scientific,
Waltham, MA, USA) and cDNAs were synthesized using RevertAid First Strand
cDNA synthesis kit (Thermo Fisher Scientific) by following the manufacturer’s
protocol. qRT-PCR was performed using ViiATM 7 RT-PCR system (Life technologies,
Grand Island, NY). The target genes were normalized by β-actin gene expression, and
the relative expression was calculated using the 2-(ΔΔnd). Primers used were mousespecific and listed in Table 5.

90

Table 5. The list of primer sequences used

Western blot analysis
Tissue lysates were prepared using RIPA buffer (Thermo Fisher Scientific)
supplemented with a protease and phosphatase inhibitors and deacetylase inhibitor
cocktail (Thermo Fisher Scientific). 20 μg of lysates was separated on 6-12.5% SDS
polyacrylamide gel, transferred to PVDF membranes, and then incubated with primary
antibody overnight at 4°C, followed by secondary antibody incubation for 1 to 1.5 hr
at room temperature. Primary antibodies including perilipin (PLIN), fatty acids
synthase (FAS), phosphorylated acetyl-CoA carboxylase at Ser79 (pACC), ACC,
phosphorylated hormone-sensitive lipase at Ser 660 (pHSL660) or at Ser565
(pHSL565), p-p65 at Ser536 (p-p65) and p65 were purchased from Cell Signaling
Technology (Beverly, MA, USA). Primary antibodies to diglyceride acyltransferase 1
(DGAT1) and adipose triglyceride lipase (ATGL) were purchased from Santa Cruz
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Biotechnology Inc. (Santa Cruz, CA, USA). Carnitine palmitoyltransferase 1A (CPT1A)
antibody was purchased from Abcam (Cambridge, MA, USA). After the incubation
with secondary antibodies, the membranes were incubated in ClairtyTM Western ECL
Blotting substrate (Bio-Rad, Hercules, CA) for 5 min and exposed to X-ray film. The
band intensities were determined using ImageJ software [National Institutes of Health
(NIH), Bethesda, MD, US].

Statistical analysis
Data are expressed as means ± SEM (n=6 per group). The statistical significance
was obtained using unpaired t tests, and the differences were considered statistically
significant at p < 0.05.

3.1.4. Results
TNFα KO reduces elevation of blood glucose and insulin and hepatic TG
accumulation in response to an HFD in mice.
We investigated whether TNFα KO attenuates HFD-induced insulin resistance
and hepatic TG accumulation in our diet-induced obesity mouse model as consistent
with the observations published by other groups (Bouter et al., 2010; De Taeye et al.,
2007; Salles et al., 2012). When compared to LFD-WT group, HFD-WT group had
significantly higher levels of fasting blood glucose and insulin and hepatic TG contents
(Fig. 18), indicating that 16-week HFD feeding developed obesity-related metabolic
comorbidities in mice, such as insulin resistance and hepatic steatosis. When compared
to HFD-fed WT group, we found that HFD-fed TNFα KO mice had markedly reduced
levels of blood glucose and insulin as well as hepatic TG. In addition, we previously
reported that TNFα KO significantly attenuated HFD-induced weight gain and fat mass
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increase in mice (under review by co-authors), which correlate to the changes in the
blood glucose and insulin and TG contents in the liver. Therefore, as demonstrated by
previous groups (Bouter et al., 2010; De Taeye et al., 2007; Salles et al., 2012), our
findings support that TNFα KO prevents HFD-induced adiposity and hepatic TG
accumulation with a concomitant improvement of insulin resistance in mice.
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Figure 18. Effect of TNFα KO on blood glucose and insulin and hepatic TG contents in HFD-fed mice. Data
are expressed as means ± SEM (n = 6 per group). #P<0.05, ##P<0.01, ###P<0.001 as compared to LFD group. *P<0.05,
**P<0.01, ***P<0.001 as compared to HFD-fed WT group
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TNFα KO prevents HFD-induced suppression of hormone-mediated lipolysis and
FAO, not de novo FA synthesis, in epididymal white adipose tissue (eWAT)
We first analyzed the mRNA expression levels of TNFα in epididymal white
adipose tissue (eWAT) from mice fed either LFD or HFD. As expected, we found that
the mRNA expression levels of TNFα in eWAT were greatly upregulated by HFD,
when compared to those from LFD-fed mice (Fig. 19 A).
Then, we evaluated the expression of proteins and genes related to lipolysis, TG
and de novo FA syntheses and FAO in eWAT from all three groups to elucidate the
role of TNFα in AT FA metabolism in diet-induced obesity. In the analysis of lipolysisrelated proteins, when compared to LFD-fed WT group, we found that HFD-fed WT
mice had greatly reduced expression levels of pHSL660 in eWAT which is an active
form of HSL that is required for its translocation to and hydrolysis of intracellular TG
droplets, whereas pHSL565, which is a quiescent form (Martin et al., 2009), remained
unchanged (Fig. 19 B & C). Also, the total ATGL protein expression was significantly
lower in HFD-fed WT mice than in LFD-fed WT ones. In parallel, the protein
expression levels of CPT1A, which mediates mitochondrial FAO, were greatly reduced
in HFD-WT group.
On the other hand, when compared to HFD-fed WT group, HFD-fed TNFα KO
mice had significantly increased protein expression levels of pHSL660, pHSL565 and
ATGL (Fig. 19 B & C). The analysis of the ratio of pHSL660 to pHSL565 further
indicates that the increase in pHSL660 was significantly greater than that in pHSL565
in eWAT by TNFα KO. Furthermore, we found that CPT1A protein expression levels
were significantly restored in HFD-fed TNFα KO mice when compared to HFD-fed
WT ones. Consistently, the mRNA expression levels of CPT1, citrate synthase (CS)
and mitochondrial cytochrome c oxidase 1 subunit (mt-CO1) were markedly increased
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in HFD-fed TNFα KO mice (Fig. 19 D), indicating that the genetic ablation of TNFα,
otherwise overexpressed by HFD, prevents HFD-induced disrupted hormone-mediated
lipolysis and FAO in AT.
Re-esterification of some portion of hydrolyzed FFAs during hormonemediated lipolysis serves as a fine-tuning mechanism for regulating intracellular FA
levels (Chitraju et al., 2017). As expected, while HFD-fed WT mice had statistically
lower expression levels of DGAT1 and PLIN in eWAT than LFD-fed WT group, HFDfed TNFα KO mice had significantly increased protein and mRNA expression levels of
DGAT1 and PLIN, when compared to HFD-fed WT mice. However, no difference on
CD36 expression was observed between HFD-fed groups (Fig. 19 B, C & E). This also
corroborates the inhibitory effects of TNFα on hormone-mediated lipolysis in AT, as
reported in in vitro adipocytes (Bézaire et al., 2009).
In addition, HFD-fed WT mice had significantly reduced expression levels of
proteins involved in de novo FA synthesis, such as pACC and FAS with a mild decrease
in ACC protein expression when compared to LFD-fed WT ones (Fig. 19 B, C & E).
In contrast, while no impacts on the protein expression levels of ACC and FAS were
observed along with no changes in the mRNA expression levels of FAS and SCD1,
TNFα KO significantly increased pACC levels which would indicate increased CPT1dependent FAO since ACC-induced CPT1 inactivity is relieved by the phosphorylation
of ACC (Galic et al., 2018).
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Figure 19. Effect of TNFα KO on fatty acid metabolism in epididymal white adipose tissue (eWAT) in HFDfed mice. (A) TNFα mRNA expression in eWAT from LFD- or HFD-fed WT group. (B) The representative images
of protein expression were shown, and (C) the relative expression was shown in bar graph. (D & E) mRNA
expression in eWAT. Data are expressed as means ± SEM (n = 6 per group). #P<0.05, ##P<0.01, ###P<0.001 as
compared to LFD group. *P<0.05, **P<0.01, ***P<0.001 as compared to HFD-fed WT group.
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TNFα KO prevents HFD-induced TG synthesis and further decreases the
suppression of de novo FA syntheses by an HFD in the liver.
The mRNA expression levels of TNFα in liver tissues from LFD-fed and HFDfed mice were first measured. Unlike eWAT, we found no increase in the mRNA
expression of hepatic TNFα gene between LFD-fed and HFD-fed mice (Fig. 20 A).
Dysregulated AT lipid metabolism in obesity increases metabolic burden to the
liver, promoting the development of hepatic steatosis (De Luca & Olefsky, 2006;
Duwaerts & Maher, 2019). To address whether the improvement of disrupted lipolysis
and FAO in AT by TNFα KO attenuates metabolic burden to the liver, we measured
the expression levels of proteins and genes related to TG and de novo FA syntheses,
FAO and hormone-mediated lipolysis in the liver. We found that HFD-fed WT mice
had significantly increased mRNA expression levels of CD36, PPARγ and DGAT1
genes in the liver when compared to LFD-fed WT group (Fig. 20 B). The protein
expression levels of DGAT1 was consistently increased by HFD (Fig. 20 C). The
development of hepatic steatosis correlates with the increase in mitochondrial FAO due
to increased FFA availability in humans (Ipsen, Lykkesfeldt, & Tveden-Nyborg, 2018;
Sanyal et al., 2001). In parallel, the expression levels of CPT1A protein and mRNA
were statistically higher in the liver from HFD-fed WT mice than in LFD-fed ones.
However, the expression of hepatic pHSL660 was barely detected, and the expression
of pHSL565 and ATGL proteins were not changed by HFD (Fig. 20 C & D), suggesting
that increased flux of exogenous FA and following TG synthesis in the liver are key
mechanisms for the development of hepatic steatosis in our HFD-induced obese mice
(Fig. 18 C). On the other hand, HFD-fed TNFα KO mice had significantly reduced
mRNA expression levels of CD36, PPARγ, CPT1A with concomitant decreases in the
protein expression levels of DGAT1 and CPT1A when compared to HFD-fed WT mice.
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Moreover, we found no impacts of TNFα KO on lipolysis-related proteins except for
the reduced expression of ATGL. Taken together, these observations suggest the
involvement of TNFα, which is overexpressed in AT, in metabolic demand of
exogenous FAs to the liver via suppressing AT lipid turnover.
A growing body of evidence suggests that de novo FA synthesis contributes to
the development of hepatic steatosis (Geisler & Renquist, 2017). However, in contrast
to the upregulation of TG synthesis, we found that HFD-fed WT mice had greatly
decreased expression levels of FAS, pACC and ACC with a concomitant decrease in
the expression of FAS and SCD1 mRNAs than LFD-fed ones. Moreover, we found
further reduced expression of those proteins and mRNAs in HFD-fed TNFα KO mice
when compared to HFD-fed WT ones. These data may indicate that, consistent with the
findings in eWAT, an increased flux of exogenous FAs from an HFD suppresses
endogenous FA synthesis in the liver. However, the additional inhibition of expression
of endogenous FA synthesis-related proteins and genes in the liver from HFD-fed
TNFα KO mice does not correlate to changes on CD36 expression.
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Figure 20. Effect of TNFα KO on fatty acid metabolism in the liver in HFD-fed mice. (A) TNFα mRNA
expression in the liver from LFD- or HFD-fed WT group. (B & E) mRNA expression in eWAT. (C) The
representative images of protein expression were shown, and (D) the relative expression was shown in bar graph.
Data are expressed as means ± SEM (n = 6 per group). #P<0.05, ##P<0.01, ###P<0.001 as compared to LFD group.
*P<0.05, **P<0.01, ***P<0.001 as compared to HFD-fed WT group.
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TNFα KO prevents inflammatory activation of eWAT in response to an HFD in
mice
Disrupted lipid metabolism correlates to macrophage accumulation (F4/80+),
and predominant polarization into inflammatory macrophages (F4/80+CD11c+CD206-)
over anti-inflammatory ones (F4/80+CD11c-CD206+) mediates inflammation and
fibrosis in tissues in obesity (Fujisaka et al., 2009). p65 phosphorylation is identified as
a key signaling pathway for macrophage survival and inflammation in AT (A. A. Hill
et al., 2015; Viatour et al., 2005). Thus, we examined the levels of p-p65, p65 and genes
related to macrophage accumulation and fibrosis in eWAT and the liver. When
compared to LFD-fed group, HFD-fed WT mice had significantly increased expression
levels of p-p65 and p65 protein in eWAT (Fig. 21 A & B). Concomitantly, we found
that pan-macrophage marker F4/80 mRNA expression was significantly higher in
HFD-fed WT mice than LFD-fed ones (Fig. 21 C). However, the upregulation of p65
phosphorylation and F4/80 gene expression in eWAT was remarkably reduced in HFDfed TNFα KO mice when compared to HFD-fed WT ones. Moreover, we found that
the expression levels of polarized macrophage markers (CD11c and CD206) and
fibrosis-related genes (TIMP1 and Col1α1) were significantly reduced by TNFα KO.
These observations corroborate that TNFα KO prevents HFD-induced suppression of
lipid turnover in AT.
On the other hand, we found no changes on the expression of p-p65 and p65
proteins and F4/80 gene in the liver among studied three groups (Fig. 21 E & F).
Particularly, the phosphorylation of p65 was barely detected from the liver lysates. Also,
we found no differences in the expression levels of polarized macrophage markers
(CD11c and CD206) and fibrosis-related genes (TGF-β, TIMP1 and Col1α1) between
HFD-fed WT and TNFα KO mice (Fig. 21 G). Given the data regarding TG synthesis
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in the liver (Fig. 20), these observations suggest that increased lipid accommodation of
the liver does not increase macrophage accumulation and fibrosis.
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Figure 21. Effect of TNFα KO on p65 phosphorylation and expression of markers for inflammation and
fibrosis in eWAT. (A-D) and liver tissues (E-G) in HFD-fed mice. (A) The representative images of protein
expression were shown, and (B) the relative expression was shown in bar graph. (C & D) mRNA expression in
eWAT. (E) The representative images of protein expression were shown. (F & G) mRNA expression in the liver.
Data are expressed as means ± SEM (n = 6 per group). #P<0.05, ##P<0.01, ###P<0.001 as compared to LFD group.
*P<0.05, **P<0.01, ***P<0.001 as compared to HFD-fed WT group.
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3.1.5. Discussion
Several lines of evidence have demonstrated that the genetic ablation of TNFα
in mice prevents HFD-induced adiposity and hepatic TG accumulation with a
concomitant improvement of glucose intolerance, while no differences in body weight
and liver fat contents were observed between WT and TNFα KO mice upon chow diet
(Bouter et al., 2010; De Taeye et al., 2007; Salles et al., 2012; Uysal et al., 1997). These
observations indicate that TNFα promotes fat deposition in tissues in response to an
HFD. However, the potential roles played by TNFα in FA metabolism in AT and the
liver in vivo have been unclear. Therefore, using TNFα KO mice, we addressed a
potential mechanism by which TNFα increases adiposity and hepatic TG accumulation
in HFD-fed mice.
Previously, we have reported that TNFα KO exhibited protection against HFDinduced weight gain and adiposity in mice as consistent with other groups (under
review by co-authors). Additionally, here we demonstrate that TNFα KO significantly
restored HFD-induced inhibition of the phosphorylation of HSL at Ser 660 and
expression of ATGL and CPT1A proteins with a concomitant increase in the mRNA
expression of genes involved in oxidative phosphorylation (CS and mt-CO1). AT
maintains metabolic flexibility through the balance between TG synthesis and FAO,
which is referred to lipid turnover, to fulfil its role as the primary energy reservoir of
the body. However, in humans with obesity, it has been revealed using
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adipocyte lipid turnover decreases with BMI and correlates positively with the amount
of cellular TG and adipocyte size and inversely with cyclic AMP-mediated lipolysis (P.
Arner et al., 2011; Frayn et al., 2012; Rydén et al., 2013). Langin et al (Langin et al.,
2005) also demonstrated disrupted adipocyte lipolysis in obese individuals with the
observation that catecholamine-induced lipolysis in isolated subcutaneous adipocytes
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was significantly inhibited in obese individuals, when compared to lean subjects. These
observations are consistently observed in our diet-induced obesity mouse model,
exhibiting significant decreases in the expression levels of proteins involved in lipolysis
and FAO in eWAT from HFD-fed WT mice when compared to LFD-fed WT mice. As
a potential mediator of disrupted lipolysis in adipocyte in obesity, several lines of in
vitro evidence (Bézaire et al., 2009; Kralisch et al., 2005; H. H. Zhang, Halbleib,
Ahmad, Manganiello, & Greenberg, 2002) have suggested TNFα with a demonstration
that, while increasing basal lipolysis through the inhibition of PLIN which coats
intracellular lipid droplets, TNFα suppresses hormone-mediated lipolysis in human
multipotent adipose-derived stem cells (hMADS) by downregulating expression of
adipocyte lipases such as HSL and ATGL. In line with this, the findings obtained from
the comparison between HFD-fed WT and TNFα KO mice indicate that TNFα would
mediate disrupted hormone-mediated lipolysis and FAO in AT in obesity. Also, we
observed that HFD-induced inhibition of PLIN protein expression in eWAT was
significantly increased by TNFα KO in mice, suggesting that TNFα may increase basal
lipolysis while suppressing hormone-mediated lipolysis in eWAT as previously
reported using hMADS (Bézaire et al., 2009). Our findings thus indicate that increased
hormone-mediated lipolysis and following FAO may provide a potential mechanism
by which TNFα KO prevents HFD-induced adiposity in mice (under review by coauthors).
Dietary FA-trafficking study using isotope tracers has demonstrated that AT
sequesters about 70% of postprandial lipids with the rest of the total hydrolyzed FAs
taken up by the liver (Fielding, 2011). This could be a supplemental mechanism for AT
to maintain its metabolic flexibility. However, the extraction amounts of lipids by the
AT in obese humans were significantly diminished, when compared to lean subjects
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(McQuaid et al., 2011). On the other hand, it was reported that the patients with NAFLD
had an upregulated expression of hepatic DGAT1, which of KO in mice protected HFDinduced hepatic steatosis by reducing the flux of exogenous FA to the liver (Nakamuta
et al., 2005; Villanueva et al., 2009). In line with this, we observed that, while the
expression of lipogenic proteins such as DGAT1 and FAS in eWAT were significantly
inhibited, hepatic lipogenic genes such as CD36, PPARγ, DGAT1 were significantly
upregulated by HFD with a consistent increase in the expression of DGAT1 protein,
which correlates to a higher hepatic TG contents in HFD-fed WT mice, compared to
LFD-fed WT ones. However, FA synthesis-related proteins and genes such as ACC,
FAS and SCD-1 were suppressed by HFD in the liver. Moreover, the phosphorylation
of HSL either at Ser 660 or Ser 565 was unchanged by HFD in the liver. These
observations indicate a close link between impaired AT fat storage and hepatic steatosis
in diet-induced obesity. On the other hand, we observed that the liver from TNFα KO
mice had a significantly lower TG contents with concomitant decreases in the
expression of DGAT1 protein and CD36 and PPARγ genes. The decreased expression
of hepatic CD36 gene and TG contents were also consistently observed by Salles et al
(Salles et al., 2012) using TNFα KO mice. Therefore, as we observed no dietary effects
on TNFα expression in the liver, these observations indicate that TNFα, which is
overexpressed by HFD and reduces lipid turnover in AT, would increase the flux of FA
to the liver and resultantly promote the development of hepatic steatosis.
It has been suggested that increased de novo FA synthesis in the liver promotes
TG accumulation and the development of hepatic steatosis (Geisler & Renquist, 2017).
In contrast with the proposed mechanism, we found that HFD significantly upregulated
CD36 gene expression, but inhibited FA synthesis as evidenced by inhibited expression
of FAS and SCD-1 genes and ACC protein. Those genes were also suppressed in eWAT
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by HFD. It is shown that DGAT1 is exclusively linked to the incorporation of
exogenous FA into TG, whereas DGAT2 mediates TG synthesis using endogenously
synthesized FA (Villanueva et al., 2009). De novo FA synthesis is shown to be
suppressed by excess exogenous long-chain FAs especially oleic acid (Hansen &
Knudsen, 1987). Furthermore, it has been shown that the suppressed expression of
tissue lipases correlates to an increase in endogenous FA synthesis (Fukuda, Ito,
Ohwada, & Fujii, 2013; Weinstock et al., 1997). Therefore, this suggests that increased
flux of FA to the tissues during an HFD feeding suppresses de novo FA synthesis and
explain no changes on FA synthesis-related expression of genes in eWAT by TNFα
KO. However, this assumption does not correlate to further decrease in the expression
of genes related to FA synthesis in the liver by TNFα, raising a question whether TNFα
KO alters the expression of tissue lipases. Indeed, although no changes were observed
in lipoprotein lipase expression in eWAT between HFD-fed groups, we found that
TNFα KO 5-fold increased the gene expression of hepatic lipase, LIPC, (Data not
shown). Hepatic lipase is a key lipolytic enzyme for hydrolyzing TG and phospholipids
from chylomicron remnants and lipoproteins (Santamarina-Fojo, González-Navarro,
Freeman, Wagner, & Nong, 2004). The genetic defect of the enzyme in humans exhibits
hyperlipidemia and a greater atherogenic risk, while its overexpression in mice
increases high-density lipoprotein levels and lowers other lipoproteins (SantamarinaFojo et al., 2004). Therefore, increased TG and lipoprotein sequestration into the liver
through LIPC upregulation in TNFα KO mice might explain the reduction of the
expression of genes related to FA synthesis in the liver.
Disrupted lipid metabolism is linked to macrophage accumulation and
inflammation in tissues in obesity (Fujisaka et al., 2009). As consistent, we observed
that suppressed hormone-mediated lipolysis and FAO correlate to the phosphorylation
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of p65 in eWAT from HFD-fed WT mice, which is a key transcriptional NF-kB subunit
for mediating macrophage accumulation and inflammation in obesity, whereas TNFα
KO significantly reduced the phosphorylation of p65 in eWAT. The reduction of p-p65
showed consistencies with the expression of macrophage markers (F4/80, CD11c and
CD206) and fibrosis markers (TIMP1 and Col1α1). The reduced expression of F4/80
mRNA in eWAT by TNFα KO was consistently observed by other groups (De Taeye
et al., 2007; Salles et al., 2012). Therefore, our findings suggest that TNFα KO prevents
HFD-induced AT inflammation and fibrosis by preventing p65 phosphorylation. On
the other hand, we observed that increased hepatic TG synthesis does not affect p65
phosphorylation and expression of macrophage markers especially F4/80, and thus no
changes by TNFα KO. This would indicate that the development of hepatic steatosis in
our diet-induced obesity model is at the early stage.
In conclusion, our findings provide molecular insight into the observations that
TNFα promotes fat deposition in AT and the liver in response to an HFD in mice. HFDinduced upregulation of TNFα expression suppresses hormone-mediated lipolysis and
FAO

in

AT,

which

in

turn

decrease

lipid

turnover

and

macrophage

accumulation/inflammation in situ and increases hepatic FA accommodation and TG
synthesis with a concomitant development of insulin resistance. In tandem with the
demonstrations by other groups, our findings support the relationship between
inflammation and abnormal fat deposition in tissues in response to an HFD in mice.
TNFα-targeted treatment would be considered as a promising way for hepatic steatosis
at the early stage and insulin resistance in obesity.
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4. The role of TNFα in retinoic acid bioavailability and its link to AT dysfunction
in Obesity
4.1. Genetic ablation of tumor necrosis factor alpha in mice increased retinoic
acid bioavailability and peroxisome proliferator-activated receptor beta/delta
expression in adipose tissue
4.1.1. Abstract
In obesity, adipose tissue (AT) is characterized by decreased lipid oxidation and
subsequently increased inflammation, commonly referred to as AT dysfunction, and
such abnormalities in AT is linked to the development of hepatic steatosis and systemic
insulin resistance. Substantial evidence characterizes tumor necrosis factor alpha
(TNFα) as a potential mediator of AT dysfunction. However, it has been still unclear
how TNFα mediates AT dysfunction. Retinoic acid (RA), a metabolite of retinol, is
known to increase adipocyte lipid oxidation through peroxisome proliferator-activated
receptor beta and delta (PPARβ/δ) expression, but its bioavailability is shown to be
reduced in AT in obesity due to decreased synthesis of RA from retinol. Thus, to
address a potential mechanism by which TNFα mediates AT dysfunction, we
characterized the relationship between TNF and RA bioavailability in blood, the liver
and epididymal white AT (eWAT) using wild-type or TNF KO mice fed a high fat
diet (HFD) and also investigated the in vitro roles of exogenous all-trans RA (ATRA)
in TNF-induced AT dysfunction using in vitro 3T3-L1 adipocytes and RAW264.7
macrophages. Although neither an HFD nor TNF KO altered RA concentrations in
plasma and liver tissues, we found that RA concentration was remarkedly reduced in
eWAT by an HFD, and such inhibition was significantly attenuated in eWAT from
HFD-fed TNF KO group with concomitant increases in the expression of RA
synthesis-related genes (RDH10 & RALDH1) and PPARβ/δ protein, when compared to
HFD-fed WT group. In 3T3-L1 adipocytes, TNF treatment significantly inhibited RA
synthesis from retinol by decreasing the expression of RDH10 & RALDH1 and
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downregulated the expression of fatty acid oxidation makers (PPARβ/δ protein and
CPT1 mRNA). On the other hand, ATRA treatment significantly upregulated the
expression of CPT1 mRNA and PPARβ/δ protein in TNFα-treated 3T3-L1 adipocytes.
Also, while adipocyte-conditioned media (CM) upregulated the expression of
inflammatory genes and p65 phosphorylation in RAW264.7 macrophages, ATRA
significantly suppressed adipocyte-CM-induced inflammatory responses by increasing
PPARβ/δ protein expression, not altering p65 phosphorylation. These findings suggest
that TNFα promotes the development of AT dysfunction by reducing RA synthesis
from retinol in adipocytes. Further investigations are warranted testing the therapeutic
roles of RA supplementation in obesity and its related complications in vivo.

4.1.2. Introduction
Retinoic acid (RA) is a metabolite of retinol, one of fat-soluble vitamins [1].
Epidemiological evidence indicates that the serum levels of RA inversely correlate with
obesity and its related metabolic complications including type 2 diabetes mellitus
(T2DM) [2,3]. The decrease in serum RA levels could pertain to low retinol intake, but
also would ascribe to increased sequestration of retinol into the expanded adipose tissue
(AT) during the development of obesity in humans regardless of dietary intake [4–7].
In support of the latter, despite adequate retinol contents in rations, diet-induced obese
mice exhibited suppressed expression of genes related to RA synthesis from retinol and
low RA levels in AT [8,9]. RDH10 is a gene encoding the primary enzyme, retinol
dehydrogenase (RDH), that initiates RA synthesis from retinol in tissues [10]. Yang, et
al [11] reported that RDH10 hetero knockout (KO) in mice leads to glucose intolerance
and reduces RA concentrations in AT which concomitantly exhibited adipocyte
hypertrophy and increased macrophage accumulation/inflammation upon chow diet.
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However, little has been appreciated regarding what suppresses RA synthesis in AT
during the development of obesity and whether low RA bioavailability would underlie
dysmetabolism and inflammation in AT.
AT serves as a primary energy reservoir of the body by storing surplus energy
in the form of triglycerides (TGs) in adipocytes and protects lipid depositions in
peripheral tissues [12]. During fasting state, the metabolic demand in AT is geared
towards lipid removal through fatty acid release and following mitochondrial fatty acid
oxidation (FAO) [12]. As AT has limits with regard to expandability and capacity to
store lipids, lipid turnover through FAO plays a key role in maintaining AT metabolic
flexibility [13]. In obese individuals, however, AT is characterized by decreased lipid
turnover due largely to decreased FAO which correlates with adipocyte hypertrophy,
followed by increased macrophage accumulation/inflammation, collectively referred to
as AT dysfunction [13,14]. As a consequence, AT in obesity has decreased ability to
accommodate dietary lipids, thereby promoting fat deposition in peripheral tissues and
systemic insulin resistance [14–16]. Tumor necrosis factor alpha (TNF) is a key
mediator that induces inflammation in tissues and is overexpressed in AT in obese
humans and rodents [17–19]. Several lines of evidence using TNF knockout (KO)
mice have demonstrated that TNF plays a key role in the development of hepatic
steatosis and systemic insulin resistance by promoting AT dysfunction in response to
an HFD [20–22]. Our recent publication further indicated that decreased FAO in AT
serves as a potential mechanism for TNF-induced AT dysfunction (Under review by
co-authors). However, molecular mechanisms by which TNF suppresses FAO in AT
remain still unclear.
Multiple clinical trials have been conducted to test the efficacy of TNF blockers
in patients with insulin resistance and type 2 diabetes mellitus (T2DM) and have raised
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safety concerns due to the association between TNF blocker and adverse events
including serious infection and congestive heart failure [23,24]. Therefore,
understanding such a missing mechanism by which obesity-induced TNF promotes
AT dysfunction would give insight into developing potential alternatives or adjuvants
for TNF blockers to minimize adverse health outcomes related to TNF blockers.
RA was previously known as an endogenous ligand for retinoid X receptors
(RXRs) and retinoic acid receptors (RARs) [25]. Moreover, it was reported that RA
increases the transcriptional activity of PPARβ/δ at the physiological concentrations
between 10 and 100 nM, while the other isoforms, PPARα and γ, remained unchanged
by RA [26,27]. PPARβ/δ is a key transcriptional factor for genes related to
mitochondrial FAO and oxidative phosphorylation and functions as a heterodimer with
RXR. Interestingly, it was also observed that luciferase activity in the cells transfected
with the responsive elements of PPARβ/δ-RXR was increased by RA and synthetic
PPARβ/δ agonist but not a RXR-selective ligand [26], suggesting that RA acts as a
PPARβ/δ agonist. Therefore, these observations would implicate that impaired RA
synthesis as observed in AT in obesity [9] would downregulate PPARβ/δ expression
or/and activity which give rise to decreased FAO and thus AT dysfunction.
Acute inflammation is known to alter retinol distribution and inhibit tissue RA
synthesis in rats [28]. There is an etiologic correlation between suppressed RA
synthesis and upregulation of TNF gene in AT in association with AT dysfunction in
obese mice. However, it is unknown whether obesity-induced TNF inhibits RA
synthesis from retinol in AT and whether exogenous RA will antagonize TNFmediated AT dysfunction. Therefore, the objectives of this study were to characterize
the role of obesity-induced TNF in RA bioavailability in AT using wild-type (WT) or
TNF KO mice fed a high fat diet (HFD) and to investigate whether exogenous all-
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trans RA (ATRA), a predominant form of RA in the body, will antagonize TNFinduced disturbed FAO in adipocytes and inflammation in macrophages stimulated
with adipocyte-conditioned media (adipocyte-CM) using in vitro 3T3-L1 adipocytes
and RAW264.7 macrophages.

4.1.3. Materials & Methods
Materials
All-trans retinoic acid (ATRA), insulin from bovine pancreas, 3-isobutyl-1methylxanthine (MIX) and dexamethasone were purchased from Sigma-Aldrich (St.
Louis, MO, USA). High-glucose Dulbecco’s modified Eagle’s medium (DMEM),
newborn calf serum (NS), fetal bovine serum (FBS), antibiotic-antimycotic (100x),
recombinant mouse TNFα and Applied biosystem® SYBR® Green PCR Master Mix
were purchased from Thermo Fisher Scientific (Waltham, MA, USA).

Animals and Biospecimen analysis
Epididymal white adipose tissue (eWAT) and blood samples were obtained
from our previously published study [under review by co-authors] which was
conducted with the approval by the Institutional Animal Care and Use Committee of
the Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts University
and the Institutional Animal Care and Use Committee of the University of
Massachusetts, Amherst. Briefly, there were three groups; one was composed of
C57BL/6 male mice fed either a low-fat diet (LFD-WT, 10 kcal% fat, n=5) or a highfat diet (HFD-WT, 60% kcal% fat, n=5), and C57BL/6 male mice homozygous for a
targeted null mutation of the TNFα locus (TNFα KO) were fed the same HFD (HFDTNFα KO, n=5). eWAT and blood samples were used to measure the concentrations of
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RA using ELIZA kits for mouse RA (MyBioSource, San Diego, CA). eWAT was also
used for protein and RNA analysis.

Cell culture
3T3-L1 preadipocytes were propagated in DMEM supplemented with 10% NS
and 1x antibiotic-antimycotic at 37°C under 5% CO2 atmosphere. To differentiate into
3T3-L1 adipocytes, post-confluent 3T3-L1 cells were exposed to a differentiation
medium, DMEM supplemented with 10% FBS, 1x antibiotic-antimycotic, 167 nM
insulin, 0.5 mM MIX and 1 μM dexamethasone (Day 0). After 48 hours (Day 2), the
cell culture medium was replaced with DMEM supplemented with 10% FBS and 167
nM insulin, refreshed every other day until fully differentiated (Day 6-8), and used for
treatment with either TNFα or TNFα and ATRA. On day 6-8 of differentiation, culture
media [adipocyte-conditioned media (adipocyte-CM)] were collected and used for
RAW264.7 macrophage experiments. RAW264.7 macrophages were propagated in
DMEM supplemented with 10% FBS and 1x antibiotic-antimycotic at 37°C under 5%
CO2 atmosphere, seeded at the density of 1 x 105 cells/mL in a 6-well plate, and used
for the treatment of adipocyte-CM, whose final concentration was 50%, in the presence
or absence of either ATRA. ATRA powder was reconstituted in 100% DMSO, lightprotected and stored at -80˚C. The presence of RA in the cultured media is unlikely as
reported with a demonstration that no RA was defected in DMEM and FBS, but did
retinol close to 0.02 μM (Sharow, Temkin, & Asson-Batres, 2012).

Medium Retinoic acid concentration measurement
Fully differentiated 3T3-L1 adipocytes were rinsed at least three times with PBS
and incubated in DMEM with 10% FBS in the absence or presence of TNFα at 10
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ng/mL for 12 hours. Then, the media were changed to 10% FBS-containing DMEM
with retinol (1 μM) and incubated for 1 hour. The media were collected and used for
measuring RA concentrations. Blood samples and eWAT lysates were also subject to
measuring RA concentrations using mouse RA ELISA kit (MyBioSource).

Quantitative real-time PCR (qRT-PCR)
For mRNA analysis, cells received a designated treatment for 12 hours. Total
RNAs were obtained using TRIzolTM reagent (Thermo Fisher Scientific), and cDNAs
were prepared using RevertAid First Strand cDNA synthesis kit (Thermo Fisher
Scientific). qRT-PCR was performed using ViiATM 7 RT-PCR system (Life
technologies, Grand Island, NY), and the expression of genes were normalized to the
expression of β-actin or 18S. The relative fold expression was calculated using the 2(ΔΔnd)

method. Primers used and their sequences are available in Table 6.

Table 6. The list of primer sequences used

Western blot analysis

115

For protein analysis, cells received a designated treatment for 1 hour. Briefly,
cell lysates were obtained using RIPA buffer supplemented with a protease and
phosphatase inhibitor tablet (Thermo Fisher Scientific). For western blot, 20 μg of
protein lysates was separated on 6-12.5% SDS polyacrylamide gel, transferred to PVDF
membranes, and incubated with primary antibody overnight at 4°C. Next day, the
membranes were incubated with secondary antibodies for 1 to 2 hours at room
temperature (RT) and exposed to ClarityTM Western ECL Blotting substrate (Bio-Rad,
Hercules, CA) for 5 min. The bands were obtained using X-ray film (Thermo Fisher
Scientific), and their intensity were determined using ImageJ software [National
Institutes of Health (NIH), Bethesda, MD, US].

Immunofluorescence (IF) analysis
Briefly, cells were grown in 4-well chamber slides and received a designated
treatment. Then, the cells were fixed with 4.5% paraformaldehyde for 20 min and
permeabilized with 0.5% Triton X-100 for 10 min at RT. For IF staining, the cells were
blocked in 2% BSA-containing PBS supplemented with 0.1% tween 20 (PBST) for 1
hour at RT, incubated with primary antibody (1:200) in PBST overnight at 4°C,
followed by the incubation with secondary antibody (1:500) overnight at 4°C. Imaging
for the immune-labeled cells was performed using EVOSTM M5000 (Thermo Fisher
Scientific), and the images were processed using the Adobe Photoshop (Adobe System,
San Jose, CA).

Statistical analysis
The in vitro data were presented as the means ± S.D of at least three independent
experiments (n=3-4). The data from animal samples were expressed as the means ±
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SEM (n=5 per group). To evaluate statistically significance, unpaired t-test was
performed, and the differences were considered being statistically significant at P <
0.05. All the data were plotted and analyzed using SigmaPlot version 11.0 (SPSS,
Chicago, IL)

4.1.4. Results
TNFα KO increases blood RA concentrations and prevents the suppression of RA
synthesis and PPARβ/δ expression in eWAT in HFD-induced obese mice
There is an etiological relationship between TNFα overexpression and impaired
RA synthesis in AT in obese mice in association with the development of AT
dysfunction. We first addressed whether RA bioavailability in blood and liver and
adipose tissues are altered by an HFD or TNFα KO in mice (Fig. 22). Neither a 16weeks of HFD feeding nor TNFα KO influences the concentrations of ATRA in plasma
and the liver (Fig. 22 A & B). However, HFD-WT group had significantly reduced
levels of ATRA in eWAT, and this reduction was mitigated by TNFα KO with a
statistical significance. Next, we questioned whether changes in RA bioavailability
correlate to those in the expression of PPARβ/δ in eWAT. We found that PPARβ/δ
protein expression was significantly reduced in eWAT from HFD-WT group when
compared to LFD-WT group, whereas eWATs from HFD-TNFα KO group had greatly
increased protein expression levels of PPARβ/δ (Fig. 22 C). In addition, we found that
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the mRNA expression levels of RA synthesis-related genes such as retinol
dehydrogenase 10 (Rdh10) and retinal dehydrogenase 1 (Raldh1) were significantly
increased in eWAT from HFD-TNFα KO group, when compared to HFD-WT group,
showing correlations with PPARβ/δ protein expression and RA concentrations (Fig. 22
D). These findings indicate that obesity-related TNFα would be an inhibitory mediator
of RA bioavailability and PPARβ/δ protein expression in AT.
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Figure 22. TNFα KO attenuates an HFD-induced impaired RA bioavailability in AT and blood in C57BL/6
male mice. (A & B) Plasma and eWAT AT concentrations. (C & D) The representative image and bar graph of
PPARβ/δ expression in eWAT. (E) The mRNA expression of RDH10 and RALDH1 genes in eWAT. Data are
expressed as means ± SEM (n=5 per group). #P<0.05, ##P<0.01, ###P<0.001 as compared to LFD group. *P<0.05,
**P<0.01, ***P<0.001 as compared to HFD-fed WT group
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TNFα inhibits RA synthesis from retinol in 3T3-L1 adipocytes
Next, we investigated whether TNFα inhibits RA synthesis from retinol in
adipocytes, which mainly consist of AT, using fully differentiated 3T3-L1 adipocytes
(Fig. 23). TNFα at 10 ng/mL significantly inhibited the expression levels of RA
synthesis-related key genes, Rdh10 and Raldh1, although no changes were observed at
0.1 or 1 ng/mL (Fig. 23 A). Also, the expression of fatty acid binding protein 5 (FABP5)
which encodes a protein that conveys RA into the nucleus was significantly inhibited
by TNFα at 10 ng/mL. Moreover, when 1 μM of retinol was given after either TNFαtreatment or none, we found that RA concentrations in the cultured media were
significantly reduced in TNFα-treated 3T3-L1 adipocytes, when compared to untreated
cells (Fig. 23 B). Given the observation that retinoic acids were not detected in FBS
and DMEM [29], these findings indicate that TNFα reduces RA bioavailability in AT
by inhibiting adipocyte RA synthesis from retinol.
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Figure 23. TNFα inhibits RA synthesis from retinol in 3T3-L1 adipocytes. (A) The mRNA expression of RDH10
and RALDH1 genes in 3T3-L1 adipocytes on the day 8 of differentiation (n=3). (B) RA concentrations in adipocytecultured media after 12-hour TNFα (10 ng/mL) treatment followed by 1-hour retinol (1 μM) incubation (n=4). Data
are expressed as means ± S.D. *P<0.05, **P<0.01, ***P<0.001 as compared to non-treated cells
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TNFα suppresses the expression of genes related to lipid synthesis and oxidation,
but ATRA co-treatment restores carnitine palmitoyltransferase 1 (CPT 1)
expression only in 3T3-L1 adipocytes
Next, we questioned whether TNFα could suppress PPARβ/δ in adipocytes
which is a transcriptional factor for CPT1 and oxidative phosphorylation-related genes
and whether such an inhibitory effect on PPARβ/δ would be prevented by ATRA
treatment. 1-hour treatment of TNFα significantly reduced the expression levels of
PPARβ/δ with no changes on the expression levels of oxidative phosphorylation-related
downstream target proteins such as ATP5A, UQCRC2, MTCO1, SDHB and NDUFB8
in 3T3-L1 adipocytes (Fig. 24 A & B). However, ATRA treatment at 10 and 100 nM
significantly increased the expression levels of PPARβ/δ, and ATRA at 100 nM greatly
upregulated the protein expression levels of ATP5A, UQCRC2, MTCO1, SDHB and
NDUFB8 in TNFα-treated 3T3-L1 adipocytes. Moreover, through IF analysis of
PPARβ/δ, we found that, while TNFα did not affect PPARβ/δ translocation when
compared to non-treated cells, ATRA at 100 nM increased the fluorescent intensity of
PPARβ/δ in the nuclei of 3T3-L1 adipocytes treated with TNFα which were stained
with DAPI (Fig. 24 C). The observations may indicate that TNFα does not affect
PPARβ/δ activity but expression as inhibiting other PPAR isoforms [31], given the 1hr treatment, whereas ATRA increases PPARβ/δ expression and activity. In addition,
the suppression of PPARβ/δ expression by TNFα in 3T3-L1 adipocytes were also
significantly increased by GW (Supplemental Fig. 2 A & B). Also, the expression
PPARβ/δ target proteins such as ATP5A, UQCRC2, and NDUFB8 were significantly
upregulated by GW in the cells. This also suggests that ATRA acts as a PPARβ/δ
agonist as GW, and impaired RA synthesis by TNFα would downregulate CPT-1
dependent FAO in adipocytes by reducing PPARβ/δ expression.
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Figure 24. TNFα inhibits genes related lipid synthesis
and oxidation, but ATRA co-treatment restores
CPT1 expression in 3T3-L1 adipocytes. The mRNA
expression of CPT1 (A) and CD36, GLUT4, PLIN and
DGAT1 (B) in fully differentiated 3T3-L1 adipocytes
after a designated treatment for 12 hours. Data are
expressed as means ± S.D (n=3). #P<0.05, ##P<0.01,
###P<0.001 as compared to non-treated cells. *P<0.05,
**P<0.01, ***P<0.001 as compared to TNFα-treated cells.

124

Supplemental Figure 1. TNFα inhibits genes
related lipid synthesis and oxidation, but GW, not
retinol, co-treatment restores CPT1 expression in
3T3-L1 adipocytes. The mRNA expression of CPT1
(A) and CD36, GLUT4, PLIN and DGAT1 (B) in
fully differentiated 3T3-L1 adipocytes after a
designated treatment for 12 hours. Data are expressed
as means ± S.D (n=3). #P<0.05, ##P<0.01, ###P<0.001
as compared to non-treated cells. *P<0.05, **P<0.01,
***P<0.001 as compared to TNFα-treated cells.

ATRA prevents TNFα-induced inhibition of expression of PPARβ/δ and its target
proteins in 3T3-L1 adipocytes
Next, we questioned whether TNFα could suppress PPARβ/δ in adipocytes
which is a transcriptional factor for CPT1 and oxidative phosphorylation-related genes
and whether such an inhibitory effect on PPARβ/δ would be prevented by ATRA
treatment. 1-hour treatment of TNFα significantly reduced the expression levels of
PPARβ/δ with no changes on the expression levels of oxidative phosphorylation-related
downstream target proteins such as ATP5A, UQCRC2, MTCO1, SDHB and NDUFB8
in 3T3-L1 adipocytes (Fig. 25 A & B). However, ATRA treatment at 10 and 100 nM
significantly increased the expression levels of PPARβ/δ, and ATRA at 100 nM greatly
upregulated the protein expression levels of ATP5A, UQCRC2, MTCO1, SDHB and
NDUFB8 in TNFα-treated 3T3-L1 adipocytes. Moreover, through IF analysis of
PPARβ/δ, we found that, while TNFα did not affect PPARβ/δ translocation when
compared to non-treated cells, ATRA at 100 nM increased the fluorescent intensity of
PPARβ/δ in the nuclei of 3T3-L1 adipocytes treated with TNFα which were stained
with DAPI (Fig. 25 C). The observations may indicate that TNFα does not affect
PPARβ/δ activity but expression as inhibiting other PPAR isoforms (Ye, 2008), given
the 1-hr treatment, whereas ATRA increases PPARβ/δ expression and activity. In
addition, the suppression of PPARβ/δ expression by TNFα in 3T3-L1 adipocytes were
also significantly increased by GW (Supplemental Fig. 2 A & B). Also, the expression
PPARβ/δ target proteins such as ATP5A, UQCRC2, and NDUFB8 were significantly
upregulated by GW in the cells. This also suggests that ATRA acts as a PPARβ/δ
agonist as GW, and impaired RA synthesis by TNFα would downregulate CPT-1
dependent FAO in adipocytes by reducing PPARβ/δ expression.
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Supplemental Figure 2. TNFα decreases PPARβ/δ
expression, but GW co-treatment increases the
expression of PPARβ/δ and oxidative
phosphorylation-related proteins in 3T3-L1
adipocytes. (A & B) The image and bar graph of
PPARβ/δ in 3T3-L1 adipocytes after a designated
treatment for 1 hour. The data were obtained from
three independent experiments (n=3). #P<0.05,
##P<0.01, ###P<0.001 as compared to non-treated
cells. *P<0.05, **P<0.01, ***P<0.001 as compared to
TNFα-treated cells.

Figure 25. TNFα decreases PPARβ/δ expression,
but ATRA co-treatment increases the expression of
PPARβ/δ and oxidative phosphorylation-related
proteins and PPARβ/δ nuclear translocation in
3T3-L1 adipocytes. (A & B) The image and bar graph
of PPARβ/δ in 3T3-L1 adipocytes after a designated
treatment for 1 hour. (C) The representative IF image
for PPARβ/δ in 3T3-L1 adipocytes after 1-hour
treatment with the indicated compounds. The data were
obtained from three independent experiments (n=3).
#P<0.05, ##P<0.01, ###P<0.001 as compared to nontreated cells. *P<0.05, **P<0.01, ***P<0.001 as
compared to TNFα-treated cells.
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ATRA inhibits inflammation activation in RAW264.7 macrophages stimulated by
50% of adipocyte-CM
Reduced RA synthesis in RDH10 hetero KO mice correlated to inflammatory
macrophage accumulation in AT [11]. Thus, we questioned whether ATRA acts as an
immunosuppressor in macrophages adjacent to adipocytes. To mimic AT environment,
we cultured RAW 264.7 macrophages and treated with adipocyte-CM (Fig. 26). The
morphology of RAW264.7 macrophages exposed to adipocyte-CM for 12 hours are
mostly changed from white, rounded shape to dark, flattened shape (Fig. 26 A). Also,
adipocyte-CM significantly upregulated the expression of pro-inflammatory genes such
as iNos, Cox-2, Il-1β, and Tnfα in RAW 264.7 macrophages (Fig. 26 B). In ATRAtreated RAW 264.7 macrophages, we found mixed cells of white, rounded shape and
dark, flattened shape. However, ATRA at either 10 or 100 nM markedly reduced
upregulation of pro-inflammatory iNos, Cox-2, Il-1β, and Tnfα genes in the cells
stimulated by adipocyte-CM. Given the observation that murine macrophages are
incapable of synthesizing RA from retinol due to the lack of membrane-associated
retinol transporter [32], these findings may indicate that ATRA produced from
adipocytes would repress inflammation activation in macrophages in AT
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Figure 26. ATRA attenuates the expression of pro-inflammatory genes in RAW 264.7 macrophages
stimulated with adipocyte-CM. (A) Phage contrast images of RAW 264.7 macrophages after a designated
treatment for 12 hours. (B) The mRNA expression of genes in Raw 264.7 macrophages. The data were expressed as
means ± S.D (n=3). #P<0.05, ##P<0.01, ###P<0.001 as compared to non-treated cells. *P<0.05, **P<0.01,
***P<0.001 as compared to cells stimulated with adipocyte-CM only.
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ATRA prevents inflammation activation in RAW 264.7 macrophages by
increasing PPARβ/δ expression without affecting the ratio of p65 phosphorylation
to p65
The transactivation of inflammatory genes in AT macrophages in obesity is
largely mediated by the phosphorylated form of the nuclear factor kappa B (NF-κB)
p65 [33,34]. However, it is reported that PPARβ/δ overexpression by GW prevents the
binding of p-p65 to its responsive element in the promoters of inflammatory genes
without altering p65 phosphorylation in murine macrophages [35]. Therefore, we
investigated whether ATRA increases PPARβ/δ expression as GW and alter p65
phosphorylation to induce expression of inflammatory genes in RAW264.7
macrophages (Fig. 27). 1-hour exposure to adipocyte-CM significantly increased the
expression levels of PPARβ/δ and p65 phosphorylation without affecting p65 protein
expression in RAW 264.7 macrophages (Fig. 27 A & B), which is consistent with the
observation during the inflammatory response in RAW264.7 macrophages stimulated
bacterial stimulus [35]. ATRA treatment, however, further upregulated the protein
expression levels of PPARβ/δ in RAW264.7 macrophages during stimulation with
adipocyte-CM for 1 hours, although we found the ratio of p-p65 to p65 was not affected
by ATRA treatment in the cells. The PPARβ/δ upregulation was statistically significant
at 100 nM when compared to non-treated, CM-stimulated cells. The ratio of PPARβ/δ
to p-p65/p65 was significantly increased by ATRA at 100 nM (Fig. 27 A & B),
suggesting that ATRA-induced PPARβ/δ expression mitigates p-p65-mediated
inflammatory response in RAW 264.7 macrophages stimulated with adipocyte-CM. In
addition, we found that adipocyte-CM for 12-hour treatment increased the fluorescent
intensity of CD11c, which is one of distinct surface markers for inflammatory
macrophages in AT [36] (Fig. 27 C). However, ATRA treatment at 100 nM
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significantly reduced CD11c fluorescent intensity in RAW 264.7 macrophages
stimulated with adipocyte-CM. Therefore, these observations may indicate that ATRA
bioavailability would play a key role in maintaining anti-inflammatory milieu in AT by
increasing PPARβ/δ expression in macrophages, and impaired RA synthesis would
give rise to inflammatory macrophage accumulation in AT as previously observed in
RDH10 hetero KO mice [11].
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Figure 27. ATRA promotes PPARβ/δ protein expression without affecting p65 phosphorylation with a
concomitant reduction in CD11c fluorescence in RAW 264.7 macrophages stimulated with adipocyte-CM. (A
& B) The image and bar graph of PPARβ/δ, p-p65 and p65 protein expression. (C) The representative image of
CD11c IF analysis. The data were obtained from three independent experiments (n=3). #P<0.05, ##P<0.01,
###P<0.001 as compared to non-treated cells. *P<0.05, **P<0.01, ***P<0.001 as compared to TNFα-treated cells.
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4.1.5. Discussion
Epidemiological studies have demonstrated that the serum levels of RA, a
metabolite form of retinol (Vitamin A), is inversely correlated to obesity and its related
metabolic complications such as T2DM (Liu, Chen, Mu, Fan, et al., 2016; Liu, Chen,
Mu, Li, et al., 2016). Although decreased serum RA levels would ascribe to low retinol
intake, animal studies have indicated that obesity increases retinol deposition and
impairs RA synthesis in tissues regardless of retinol intake, especially AT where RA is
abundantly found along with the liver (Harris & Dawson-Hughes, 2007; ThomasValdés et al., 2017; Wortsman et al., 2000; M. Zhang et al., 2015). This is also
supported by the observations that vitamin D, another fat-soluble vitamin, is
increasingly deposited in AT in obese individuals, lowering the bioavailability of
vitamin D in the body (Harris & Dawson-Hughes, 2007; Wortsman et al., 2000)
Moreover, upon chow diet, mice with hetero KO of RDH10, a gene encoding the key
enzyme that is responsible for RA synthesis, exhibits decreased RA concentrations,
disturbed lipid metabolism and inflammation in AT (AT dysfunction) which correlate
to increased body weight and insulin resistance (Farjo et al., 2011). These observations
indicate that RA synthesis in AT is impaired in obesity, and reduced RA bioavailability
contributes to the development of AT dysfunction, a central mechanism leading to
morbid obesity and insulin resistance (Goossens & Blaak, 2015). However, little has
been appreciated regarding what mediates the suppression of RA synthesis in AT and
whether exogenous RA attenuates AT dysfunction in obesity. To the best of our
knowledge, we first characterized the inverse relationship between TNFα and RA
synthesis in AT in diet-induced obese mice. In eWAT in which we previously reported
a significant increase in the expression levels of TNFα [under review by co-authors],
we found that RA synthesis-related genes (RDH10 and RALDH1) and RA
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concentrations were significantly reduced by an HFD, whereas those inhibitions were
attenuated in AT from TNFα KO mice. Natacha et al (Shaw et al., 2003) suggests RA
as a potential activator of PPARβ/δ in vitro, a transcriptional factor for genes related
FAO and oxidative phosphorylation. It was reported that the mRNA expression levels
of AT PPARβ/δ is downregulated in diet-induced obese mice (Berry & Noy, 2009).
Consistently, we found that the expression of PPARβ/δ protein and its downstream
CPT1 gene in AT was significantly inhibited by an HFD, and its inhibition was
prevented in TNFα-deficient group. In addition, we found that TNFα significantly
inhibited the expression levels of RDH10 and RALDH1 and also RA synthesis from
retinol in 3T3-L1 adipocytes with concomitant inhibitions of PPARβ/δ and its
downstream CPT1 gene. Therefore, these observations indicate that obesity-related
TNFα inhibits RA synthesis from retinol in adipocyte, lowering RA bioavailability in
AT. In the liver, on the other hand, we found no changes in RA concentrations by either
an HFD or TNFα KO. As reported in our previous study [under review by co-authors],
the expression of either TNFα or other inflammatory genes in the liver was not altered
by an HFD which could corroborate the inhibitory roles of TNFα in RA synthesis from
retinol in situ.
Substantial evidence suggests TNFα as an important mediator of AT
dysfunction and subsequently metabolic comorbidities such as obesity and insulin
resistance (Hotamisligil et al., 1995; Parameswaran & Patial, 2010). In our recently
published study, we have demonstrated that TNFα-induced impairment of FAO
underlies increased adiposity and metabolic dysfunction of AT in diet-induced obese
mice [under review by co-authors]. However, a molecular mechanism by which TNFα
downregulates adipocyte FAO has been unclear. FAO is initiated by transferring fatty
acid substrate, fatty acyl-CoA molecule, across the mitochondrial membrane through
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carnitine shuttle system (CPT1) (Schulz, 2013). Therefore, CPT1 plays a pivotal role
in the regulation of mitochondrial FAO in adipocytes (Schulz, 2013). In this regard, it
was reported that TNFα-treatment leads to condensation of mitochondria and reduced
intracellular ATP production in 3T3-L1 adipocytes (Chen et al., 2010). In line with the
observation, we found that TNFα significantly reduced the expression levels of
PPARβ/δ and its downstream targets such as oxidative phosphorylation-related proteins
and CPT1 gene in 3T3-L1 adipocytes. Given the observations that TNFα inhibits RA
synthesis from retinol in eWAT and 3T3-L1 adipocytes in this study and that RA acts
as a potential endogenous activator for PPARβ/δ, these observations may indicate that
decreased RA may serve as a potential mechanism by which obesity-related TNFα
inhibits mitochondrial FAO and ATP production in AT, leading to AT dysfunction.
Interestingly, we found that ATRA co-treatment with TNFα at the
physiologically concentration (10 and 100 nM) in humans and mice (Cifelli & Ross,
2006) significantly restored the expression levels of PPARβ/δ and also increased the
expression levels of oxidative phosphorylation-related proteins and CPT1 gene in 3T3L1 adipocytes. Consistently, Daniel et al (Berry & Noy, 2009) reported that, while
PPARβ/δ mRNA expression was reduced in eWAT by a high-fat/high-sucrose diet,
ATRA supplementation through subcutaneous implanting significantly increased
PPARβ/δ mRNA expression close to the lean group. With regard to the role of ATRA
in the regulation of PPARβ/δ, Kim et al (J. Kim, Wellmann, Smith, & Johnson, 2018)
reported that ATRA at 10 to 100 nM significantly increased PPARβ/δ protein and
mRNA expression in bovine satellite cells. Also, ATRA at 100 nM promoted the
nuclear translocation of PPARβ/δ in the cells (J. Kim et al., 2018). In addition to the
increased protein expression of PPARβ/δ by ATRA, we consistently found that
PPARβ/δ immunostaining was highly localized in the nuclei of 3T3-L1 adipocytes in
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the co-presence of ATRA and TNFα when compared to TNFα-treated adipocytes.
These observations thus indicate that exogenous RA may antagonize the inhibitory role
of TNFα in mitochondrial FAO in adipocytes by increasing PPARβ/δ expression and
translocation into nucleus.
In obesity, disturbed adipocyte lipid metabolism correlates with increased
inflammation in adjacent macrophages, constituting local and systemic sustained
inflammation (Goossens & Blaak, 2015). Reduced RA bioavailability in AT from
RDH10 hetero KO mice correlates with increased adiposity and inflammatory
macrophage infiltration in situ and impaired glucose tolerance (Yang et al., 2018).
Several lines of evidence indicate that ATRA suppresses inflammatory responses and
expression of distinct surface markers that recognize inflammatory macrophages, such
as CD11c, in murine macrophages (Babina & Henz, 2003; Vellozo et al., 2017). In line
with the previous observations, we found that the inflammatory responses activated by
adipocyte-CM in RAW 264.7 macrophages were significantly attenuated by ATRA
treatment at 10 and 100 nM, reducing the expression levels of iNos, Cox-2, Il-1β and
Tnfα. However, a potential mechanism for the anti-inflammatory effects of ATRA on
macrophage inflammation has been unclear. Phosphorylated p65 subunit, one of the
NF-κB family proteins, plays an important role in inducing pro-inflammatory genes
and macrophage survival in obesity (Giridharan & Srinivasan, 2018; A. A. Hill et al.,
2015; Viatour et al., 2005). PPARβ/δ overexpression by a PPARβ/δ agonist (GW0742)
is shown to interfere with the binding of p-p65 to its responsive element without
affecting p65 phosphorylation in J774.A1 macrophages (Zingarelli et al., 2010),
suggesting the balance between PPARβ/δ and p-p65 regulates macrophage
inflammation. In the present study, we found that ATRA did not alter the
phosphorylation of p65 but significantly increased the expression levels of PPARβ/δ in
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RAW264.7 macrophages. Thus, the ratio of PPARβ/δ and phosphorylated p65 was
significantly increased by ATRA in the cells, suggesting that ATRA prevents
macrophage inflammation induced by adipocyte-CM through increasing PPARβ/δ
expression. Furthermore, we found that ATRA significantly reduced the fluorescent
intensity of CD11c on macrophages, a distinct surface marker for inflammatory
macrophages. Since murine macrophage does not contain retinol transporters and has
no capability for RA synthesis in vivo (Niu, Hadwiger, Fujiwara, & Welch, 2016), RA
bioavailability which is mediated by adipocyte RA synthesis would play an important
role in the regulation of inflammation in AT, and impaired RA synthesis would promote
the cross-talk between adipocyte and macrophage to constitute sustained inflammation
in situ.
In conclusion, we have demonstrated the relationship between TNFα and
impaired RA synthesis in AT, which downregulates FAO in adipocytes in vivo and in
vitro. In addition, we found that exogenous RA promotes FAO in TNFα-treated 3T3L1 adipocytes and suppresses inflammation in RAW 264.7 macrophages stimulated by
adipocyte-CM by increasing PPARβ/δ expression in both cell types. Previously, we
have demonstrated that TNFα leads to adiposity and insulin resistance by promoting
AT dysfunction. In this regard, our data indicate the importance of RA bioavailability
in the regulation of adipocyte FAO and macrophage inflammation, and the failure of
RA synthesis by TNFα in AT would contribute to the development of AT dysfunction,
adiposity and insulin resistance. Therefore, this warrants further investigations in terms
of the role of RA supplementation, not retinol, in obesity and its related complications
through pre-clinical and clinical studies.
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5. Summary and Future Directions
In obesity, AT exhibits decreased lipid uptake, impaired lipid turnover and
augmented macrophage inflammation/accumulation, which are collectively referred to
as AT dysfunction. Substantial evidence characterizes AT dysfunction in obesity as
central mechanism leading to metabolic comorbidities such as chronic inflammation,
hepatic steatosis and insulin resistance, all of which are well-known risk factors for the
leading causes of death including NAFLD, T2DM and CVD. However, what mediates
the development of AT dysfunction in obesity has been unclear, and there are few
dietary intervention and pharmaceutics that target AT dysfunction for the treatment of
obesity and its related metabolic complications (Chapter 1).
In attempts to provide scientific foundations for potential dietary means that
mitigate the development of AT dysfunction in obesity and to advance the etiological
understanding of AT dysfunction in obesity, proposed dissertation works have been
conducted and presented above. We have identified four potential dietary bioactives
that might mitigate the development of AT dysfunction in obesity with potential
molecular mechanisms addressed (Chapter 2). First, ARN, anthocyanidin-rich aronia
extract, significantly inhibited macrophage inflammation and accumulation in adipose
SVF in diet-induced obese mice, showing correlations with the marginal improvement
of hyperglycemia and dyslipidemia. The inhibition of the NF-κB p65 phosphorylation
in macrophages is identified as a potential molecular target for ARN to exert antiinflammatory potentials (Chapter 2.1). Second, FMN, an isoflavone abundantly found
in red clover and Huangqi (Astragalus roots), enhanced adipocyte FAO by increasing
AMPK phosphorylation and preadipocyte differentiation into adipocyte via PPARγ in
vitro (Chapter 2.2). Third, both proanthocyanidins-rich cranberry extract (CBE), and
SFN, a major bioactive compound of cruciferous vegetables (brussels sprout and
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broccoli), have anti-inflammatory potentials on macrophage stimulated with LPS in
vitro. Inhibition of p65 phosphorylation and upregulation of HDAC3 protein expression
are identified as potential mechanisms for the inhibitory effects of CBE and SFN on
macrophage inflammation (Chapter 2.3 & 2.4). Therefore, these dietary bioactives
warrant further investigation using pre-clinical or clinical models to test in vivo and
clinical relevance of the findings.
In addition, we have identified that TNFα, a potent mediator of tissue
inflammation, promotes the development of AT dysfunction and insulin resistance in
diet-induced obese mice (Chapter 3). Through the comparison between WT and TNFα
KO groups, both fed an HFD, we found that TNFα KO increases the expression of
proteins involved in hormone-mediated lipolysis and FAO in AT with concomitant
decreases in macrophage inflammation and accumulation. Also, TNFα KO reduces
hepatic TG accumulation by decreasing the expression of genes related to lipid uptake.
TNFα expression was unchanged in the liver but significantly upregulated in AT in
diet-induced obese mice, when compared to LFD-fed mice. These observations thus
indicate that TNFα, which is overexpressed in AT in obesity, leads to AT dysfunction,
leading to hepatic steatosis and insulin resistance. The impairment of FAO in AT is
suggested as a key mechanism for the development of AT dysfunction.
The potential mechanisms by which TNFα impairs FAO in AT are addressed in
Chapter 4. Retinoic acid (RA) is a metabolite of retinol (dietary vitamin A) and is
suggested as a potential agonist of the transcriptional factor PPARβ/δ which induces
genes involved in FAO. We have found that TNFα impairs RA synthesis from retinol
in adipocytes by downregulating RA synthesis-related genes in vivo and in vitro. Also,
TNFα significantly inhibited the protein expression of PPARβ/δ and its downstream
target CPT1 expression in 3T3-adipocytes. Moreover, the treatment of all-trans RA
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(ATRA), a predominant form of RA in the body, significantly restored CPT1
expression by increasing the protein expression and activity of PPARβ/δ in 3T3-L1
adipocyte treated with TNFα as does a PPARβ/δ agonist (GW0742). However, retinol
failed to do so in TNFα-treated adipocytes. Furthermore, we found that ATRA
significantly inhibited inflammatory responses in RAW264.7 macrophages stimulated
by adipocyte-conditioned media (CM) by increasing PPARβ/δ expression. Therefore,
impaired RA synthesis would serve as a potential mechanism by which TNFα
downregulates FAO in adipocytes and thus AT dysfunction. Conversely, providing
supplemental RA or TNF blockers would mitigate the development of AT dysfunction
in obesity. However, several clinical trials have raised safety concerns on the efficacy
of TNF blockers on patients with T2DM and CVD due to the potential associations
between TNF blockers and increased infection and congenital heart failure. Thus,
further studies are needed to address whether exogenous RA would be a potential
adjuvant or alternative against AT dysfunction using preclinical and clinical models.
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